



Systematic Review

# Exercise Training-Induced Extracellular Matrix Protein Adaptation in Locomotor Muscles: A Systematic Review

Efpraxia Kritikaki <sup>1</sup>, Rhiannon Asterling <sup>1</sup>, Lesley Ward <sup>1</sup>, Kay Padget <sup>1</sup>, Esther Barreiro <sup>2</sup> and Davina C. M. Simoes <sup>1</sup>,\*

- <sup>1</sup> Faculty of Health and Life Sciences, Northumbria University Newcastle, Newcastle upon Tyne NE1 8ST, UK; effie.kritikaki@northumbria.ac.uk (E.K.); rhiannon.ast@gmail.com (R.A.); lesley.ward@northumbria.ac.uk (L.W.); kay.padget@northumbria.ac.uk (K.P.)
- Pulmonology Department, Lung Cancer and Muscle Research Group, Hospital del Mar-IMIM, Parc de Salut Mar, Health and Experimental Sciences Department (CEXS), Universitat Pompeu Fabra (UPF), CIBERES, 08002 Barcelona, Spain; ebarreiro@imim.es
- \* Correspondence: davina.simoes@northumbria.ac.uk

Abstract: Exercise training promotes muscle adaptation and remodelling by balancing the processes of anabolism and catabolism; however, the mechanisms by which exercise delays accelerated muscle wasting are not fully understood. Intramuscular extracellular matrix (ECM) proteins are essential to tissue structure and function, as they create a responsive environment for the survival and repair of the muscle fibres. However, their role in muscle adaptation is underappreciated and underinvestigated. The PubMed, COCHRANE, Scopus and CIHNAL databases were systematically searched from inception until February 2021. The inclusion criteria were on ECM adaptation after exercise training in healthy adult population. Evidence from 21 studies on 402 participants demonstrates that exercise training induces muscle remodelling, and this is accompanied by ECM adaptation. All types of exercise interventions promoted a widespread increase in collagens, glycoproteins and proteoglycans ECM transcriptomes in younger and older participants. The ECM controlling mechanisms highlighted here were concerned with myogenic and angiogenic processes during muscle adaptation and remodelling. Further research identifying the mechanisms underlying the link between ECMs and muscle adaptation will support the discovery of novel therapeutic targets and the development of personalised exercise training medicine.

**Keywords:** extracellular matrix; skeletal muscle; glycoproteins; proteoglycans; collagens; exercise training; ageing; remodelling; adaptation; myogenesis



Citation: Kritikaki, E.; Asterling, R.; Ward, L.; Padget, K.; Barreiro, E.; C. M. Simoes, D. Exercise
Training-Induced Extracellular Matrix
Protein Adaptation in Locomotor
Muscles: A Systematic Review. *Cells*2021, 10, 1022. https://doi.org/
10.3390/cells10051022

Academic Editor: Robert Wessells

Received: 30 March 2021 Accepted: 20 April 2021 Published: 26 April 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

# 1. Introduction

Skeletal muscle mass accounts for 40% of total body mass. Muscle is a highly plastic tissue, and adaptation is seen after increased locomotory and metabolic demands of exercise training. Adaptation in terms of altered muscle physiology and improved performance varies greatly according to the activities imposed, such as force, duration, as well as individual's capacity to respond, which is controlled by their genetic makeup [1].

Ageing is associated with progressive decline in skeletal muscle mass, muscle strength and regenerative capacity [2]. Weakened muscles increase the likelihood of injury and ineffective repair processes, negatively affecting quality of life. Exercise training is applied as a therapeutic intervention capable of improving aged muscle regeneration, muscle strength and muscle mass [3–5]. Most of the investigations have traditionally focused on elucidating the phenotypic changes on muscle strength, size and fibre type distribution. At the cellular and molecular level, several markers of cellular anabolism and catabolism have been investigated [2,3,6]. However, studies on the effect of exercise training promoting muscle extracellular matrix (ECM) adaptation are limited and have been frequently overlooked.

Cells 2021, 10, 1022 2 of 28

The intramuscular ECM is widely distributed throughout muscle tissue, maintaining its structure. The ECM endomysium embeds the individual muscle fibres and the neighbouring myofibers are organized into fascicles encased by the perimysium. The whole muscle is ensheathed by another layer of ECM connective tissue named the epimysium [7]. Intramuscular ECMs provide mechanical support to muscle tissue, nerves and blood vessels. Recent research has demonstrated that the ECM plays an important role in muscle growth [8] and repair processes [9], as well as the transmission of contractile force [10]. Nevertheless, the role of ECM adaptation on muscle regeneration and remodelling after exercise training stimulus is still unclear. The intramuscular ECM adaptation seen during ageing has been reviewed elsewhere [11].

As a post-mitotic tissue, the homeostasis of the skeletal muscles depends on the capacity of the satellite cells to adapt and regenerate. Under normal conditions, adult muscle turnover as result of daily life activities relies on sporadic proliferation and fusion of satellite cells to muscle fibres. Satellite cells are found in a cell niche, which consists of a mesh of components containing a mixture of glycoproteins and proteoglycans and growth factors. The ECMs in the niche provide a dynamic environment, transmitting mechanical and biochemical signals. The function of these ECM molecules is to maintain satellite cell quiescence, activation, proliferation and differentiation [9,11,12].

Exercise training is the most potent strategy to improve muscle fibre cross-sectional area. This intervention remodels peripheral skeletal muscle architecture and alters the ECM expression involved in this process [13–15]. However, the extent to which ECMs contribute to the regeneration and remodelling of the skeletal muscle upon exercise training is still unclear. The aim of this systematic review is to provide up-to-date information on the effect of exercise training inducing ECM adaptation and the involvement of ECMs on skeletal muscle remodelling.

### 2. Materials and Methods

This systematic review was compiled using guidelines described in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [16]. The review protocol is registered with the International Prospective Register of Systematic Reviews (PROSPERO ID: CRD42021206259).

## 2.1. Search Strategy

A literature search of online databases, PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), Scopus, and CINAHL was conducted from their inception to March 2021. These databases were chosen due to their relevance in the field, use in other systematic reviews [17–19] and in consultation with a university librarian. All databases were accessed via the Northumbria University library platform. A search on PEDro database did not retrieve study results framework. In addition to the database search, citations from studies in the field were screened for the criteria and inserted as other sources.

To develop the search strategy, relevant terminology was determined from published reviews associated with ECM in skeletal muscle and with exercise training [11,20]. Following this, search strings based on a combination of a mix of Medical Subject Headings (MeSH) or free text words related to "extracellular matrix proteins", "exercise", "activity", "skeletal muscle remodelling", "cachexia" and "skeletal muscle wasting" were used to form the PICO (population, intervention, comparators, outcome) framework (Supplementary Table S1).

### 2.2. Study Selection and Data Extraction

Peer reviewed studies published in the English language and involving healthy human participants were eligible to be included in this systematic review. Studies evaluating the effect of exercise training intervention on primary or secondary outcome demonstrating ECM expression at mRNA and protein level were included. ECM-related molecules

Cells 2021, 10, 1022 3 of 28

were not part of the outcome search. No chronological and study design limitations were determined.

Studies exclusively testing animal or in vitro models were excluded from this systematic review. Studies describing immobilization and/or disuse interventions, as well as studies testing the effect of a single bout of exercise were excluded. Other studies excluded were those that analysed non-peripheral skeletal muscle, pharmacological interventions, and those on neuromuscular pathologies. Studies that did not contain any ECM marker in their outcomes were also excluded from the current review.

Selected outcomes were exported to EndNote software (Thomson Reuters, New York, NY, USA). Duplicates were removed using the systematic review management software program Rayyan (Qatar Computing Research Institute, Doha, Qatar). Titles and abstracts were screened by two reviewers (E.K. and R.A.), articles were fully text read and assessed for inclusion eligibility. Any disputes were resolved by a third reviewer (D.C.M.S.). Data were extracted individually by two reviewers (E.K. and R.A.).

# 2.3. Quality Assessment

The outcomes were assessed for risk of bias (E.K., R.A.), and discrepancies resolved (E.K.). As the studies included randomized controlled trials (RCTs) or non-RCTs, the revised versions of Cochrane Collaboration's tool (RoB2) and ROBINS-I were used to assess the risk of bias, respectively [21-23]. ROBINS-I is the preferentially recommended tool to evaluate the risk of bias of non-RCTs [23]. This tool was specifically developed to evaluate the risk of bias estimating the comparative effectiveness of interventions in studies not adopting randomisation in allocating units (individual or cluster of individuals) into comparison groups [21]. Additionally, bias domains that are included in ROBINS-I considered the pre-intervention, at-intervention and post-intervention periods. Whereas RoB2 is a suitable tool for assessing the risk of bias for RCTs [23]. RoB2 domains of assessing bias included signalling questions that were based on the randomisation process, deviations from the intended interventions, missing outcome data, missing reported results, selections of the reported results and an overall bias [22]. The interpretation of the domain-level and overall risk of bias judgements in both assessment tools are "Low risk", "Moderate risk", "Serious risk" and "Critical risk" of bias, which were calculated from the checklist scores according to ROBINS-I and RoB2 guidance [21,22]

### 3. Results

The systematic search of the online database identified 2236 articles. Twelve articles were added from other sources. All articles were screened using the eligibility and exclusion criteria. The PRISMA flow diagram (Figure 1) summarizes the search strategy and the study selection process.

Of the 21 studies included in the systematic review, 18 were non-RCT of pre–post study design [24–41] and 3 RCTs [42–44]. Even though our systematic review focuses on healthy subjects, two studies were on clinical populations [34,44]. However, no fibrosis or other neuromuscular pathologies were observed in these studies. The exercise training interventions prescribed were aerobic exercise training (AET) [30,31,35,37,39–41,44], resistance training (RET) [24,25,28,33,34,36,42,43], combined aerobic and resistance training (CT) [26,27,32], electrical stimulation (ES) [29] and one comparing resistance training, high-intensity interval training (HIIT) and combined training after a sedentary period [38]. The duration of the exercise interventions ranged from 5 to 13 weeks, the frequency was 2 to 9 sessions per week, and the mean calculated (duration x number of sessions) dosage was 35.3 hrs. We were able to accurately estimate dosage in 18 out of the 21 studies included. Notably, the training duration was different among age groups. In older age populations, longer training intervention for more than 9 weeks was preferably prescribed, whereas in the younger age groups, the training tended to be shorter than 9 weeks. The characteristics of the studies' interventions are presented in Table 3, with the clinical studies placed at

Cells 2021, 10, 1022 4 of 28

bottom of the Tables. No adverse events were mentioned throughout the duration of these studies.




Figure 1. PRISMA flow diagram of the identification and selection process.

# 3.1. Study and Subject Characteristics

A total of 402 healthy individuals, with an average age of 46.8 years old (19–77.4 years old) and 85 individuals from a clinical population with an average age 57.9 years participated across the studies. The majority of studies included only male participants representing 69% of the total population, four studies included males and females [29,36,38,41], and two studies exclusively females [34,43]. Among the healthy individuals, 69% were male and 31% female. The majority of the studies involved either a young group (<38 years old) with an average age 25.1  $\pm$  1.8 years old or an old group with an average age 65.7  $\pm$  9.9 years old. Direct comparison of the effect of exercise on ECMs in young and old populations was limited to data from only two studies [36,38]. A summary of participants' characteristics and physiological changes as result of exercise intervention is shown in Table 3.

Cells **2021**, 10, 1022 5 of 28

**Table 1.** ROBINS-I quality assessment scores for the non-RCTs included studies.

Author	Bias Due to Confounding	Bias in Selection of Participants into the Study	Bias in Classification of Interventions	Bias Due to Deviations from Intended Interventions	Bias Due to Missing Data	Bias in Measurement of Outcomes	Bias in Selection of the Reported Result	Overall Bias
Damas et al., 2018 [24]	Low	Low	Low	Low	Low	Low	Low	Low
Deshmukh et al., 2021 [25]	Low	Low	Low	Low	Low	Moderate	Low	Moderate
Hjorth et al., 2015 [26]	Low	Moderate	Low	Low	Low	Unclear	Low	Moderate
Kanzleiter et al., 2014 [27]	Low	Low	Low	Low	Low	Unclear	Low	Moderate
Karlsen et al., 2020 [28]	Low	Low	Low	Low	Low	Moderate	Low	Moderate
Kern et al., 2014 [29]	Moderate	Low	Low	Low	Low	Low	Low	Moderate
Makhnovskii et al., 2020 [30]	Low	Moderate	Low	Unclear	Low	Low	Low	Moderate
Nishida et al., 2010 [31]	Low	Low	Low	Low	Low	Low	Low	Low
Norheim et al., 2011 [32]	Low	Unclear	Low	Low	Low	Low	Low	Moderate
Norheim et al., 2014 [33]	Low	Low	Low	Low	Low	Unclear	Low	Moderate
Olstad et al., 2020 [34]	Unclear	Low	Low	Low	Low	Low	Low	Moderate
Radom-Aizak et al., 2005 [35]	Low	Low	Low	Low	Low	Low	Unclear	Moderate
Raue et al., 2012 [36]	Low	Low	Low	Low	Low	Low	Low	Low
Riedl et al., 2010 [37]	Low	Low	Low	Low	Low	Low	Low	Low
Robinson et al., 2017 [38]	Low	Low	Low	Low	Low	Low	Low	Low
Timmons et al., 2010 [39]	Low	Low	Low	Low	Low	Low	Low	Low
Valdivierso et al., 2017 [40]	Low	Low	Low	Low	Low	Low	Low	Low
Walton et al., 2019 [41]	Low	Low	Low	Low	Moderate	Low	Low	Moderate

 $\textbf{Table 2.} \ \ RoB\ 2\ quality\ assessment\ scores\ for\ RCTs\ included\ studies.$ 

Author	Randomization Process Bias	Deviation from the Intended Intervention Bias	Missing Outcome Bias	Measurement of the Outcome Bias	Selection of Reported Results Bias	Overall Risk of Bias
Alghadir et al., 2016 [42]	High	Low	Low	High	Moderate	High
Fragala et al., 2014 [43]	Low	Low	Low	Unclear	Low	Moderate
Kim et al., 2015 [44]	Low	Low	Low	Unclear	Low	Moderate

Cells **2021**, 10, 1022 6 of 28

**Table 3.** Characteristics of the included studies, their participants and muscle remodelling outcome.

First Author, Year of Publication	Country	Participant Group (n); Sex (n, %)	$\begin{aligned} \mathbf{Age} & \pm \mathbf{SD} \\ \mathbf{or} & \pm \mathbf{SEM(*)} \end{aligned}$	Study Design	Experimental Group Intervention	Experimental Duration and Frequency, Dosage (h)	Attrition (Reasons)	Outcome Measures	Δ Muscle Remodelling Post-Training (within Group)	Δ Muscle Remodelling Post-Training (between Groups)
Damas et al., 2018 [24]	Brazil	Exercise (9); Male (9, 100%)	26 ± 2	Pre-post study	RET: it involved two exercises for lower body.	10 weeks (2x/week) Dosage = N/A	<sup>1</sup> participant (male) removed	N/A	N/A	N/A
Deshmukh et al., 2021 [25]	Denmark	Exercise (5); Male (5, 100%)	$24\pm1{}^*$	Sub-cohort of pre–post study	AET: participants performed indoor cycling exercise (intensity ranged from 75–90% of maximal heart rate): 3 out of 4 sessions performed at home, 1 out of 4 at the laboratory.	12 weeks (4x/weeks) Dosage = 48	None	NA	NA	NA
	8	Exercise (12);Male (7, 58.3%),	70.5 ± 6.9		Supervised RET:			Muscle strength/ capacity		
		Female (5, 41.7%)			60–90 min (≈70–85% of RM).			Leg extension strength (kg)	Exercise: † 29.0% (p < 0.001) Control: NS	NS
Fragala et al., 2014 [43]	USA	Control (11); Male (6, 54.5%), Female (5, 45.5%)	69.6 ± 5.5	Pilot RCT	Maintenance of normal physical activities.	6 weeks (2x/week) Dosage = 12–18	None	Muscle quality (relative strength)	Exercise: † 28.0% (p < 0.001) Control: NS	NS
[10]								Body composition LBM (kg)	Exercise: † 0.2% (NS) Control: NS	NS
								Muscle architecture	College	
								Muscle cross-sectional area (CSA) (cm²)	Exercise: † 8.3% (NS) Control: NS	NS
								Muscle strength/ capacity		
					S CT			Leg extension strength (kg)	† 9.6% (p < 0.001)	
Hjorth et al., 2015 [26]	Norway	Exercise (26); Male (26, 100%)	51.2 ± 6.6	Pre-post study	Supervised CT: 2 intervals bicycle sessions and 2 whole body strength-training sessions per week. Each session	12 weeks (4x/week) Dosage = 48	None	Body composition Fat mass (L) Muscle architecture	↓ 8.2% (p < 0.001)	N/A
					lasted 1 h.			Thigh muscle area (cm²)	† 7.5% ( $p < 0.001$ )	
								Ventilatory changes VO <sub>tmax</sub> (mL/kg*min)	† 11.2% (p < 0.001)	
Kanzleiter et al., 2014 [27]	Norway/Germany	Exercise (26); Male (26, 100%); Normal glucose group (13); Pre-diabetes group (13)	$51.2 \pm 6.6$	Pre–post study	Supervised CT: 2 intervals bicycle sessions and 2 whole body strength-training sessions per week. Each session lasted 1 h.	12 weeks (4x/week) Dosage = 48	None	N/A	N/A	N/A

 Table 3. Cont.

First Author, Year of Publication	Country	Participant Group (n); Sex (n, %)	$egin{aligned} \mathbf{Age} \pm \mathbf{SD} \ \mathbf{or} \pm \mathbf{SEM(*)} \end{aligned}$	Study Design	Experimental Group Intervention	Experimental Duration and Frequency, Dosage (h)	Attrition (Reasons)	Outcome Measures	Δ Muscle Remodelling Post-Training (within Group)	Δ Muscle Remodelling Post-Training (between Groups)
Karlsen et al., 2020 [28]	Dermark	Young (7): Male (7, 100%) Older (19); Male (19, 100%)	25±3 67±4	Pre–post study	Supervised heavy-load RET: sessions involved 3 exercises for lower body and 2 optional for upper body	13 weeks (3x/week) Dosage = N/A	<sup>2</sup> Five old and two young participants did not complete th intervention.	Muscle strength/ capacity  Isometric knee extensor peak torque (Nm)  Body composition Thin lean mass (kg)  Muscle architecture CSA VL (µm²)  CSA QF (µm²)  CSA type I fibres (µm²)  Type I fibres (µm²)	Young: † 14.4 % (p < 0.01) Older: † 14.3% (p < 0.001) Young: † 11.9% (p < 0.05) Older: † 9% (p < 0.05)  Young: † 6.7% (p < 0.001) Older: † 6% (p < 0.001) Older: † 6% (p < 0.001) Older: † 14.5% (p < 0.001) Young: † 11.9% (p < 0.001) Older: † 14.5% (p < 0.001) Older: † 1.9% (p < 0.001) Older: † 1.9% (p < 0.001) Young: † 10.2% (NS) Older: † 5.7% (NS) Older: † 5.5% (p < 0.001) Young: † 1.2% (NS) Older: † 2.5% (p < 0.001) Young: 1.2% (NS) Older: † 1.9% (NS) Older: † 1.9% (NS) Older: † 1.9% (NS)	N/A
Kern et al., 2014 [29]	Italy/Austria	Exercise (16); Male (8, 50%), Female (8, 50%)	73.1±6.9	Pre-post study	ES training at home: performed with a two-charnel custom-built battery-powered stimulator3×10 min each session.	9 weeks (2x/week for the first 3 weeks 3x/week for the following 6 weeks) Dosage = 12	and ; None	Muscle strength/ capacity Torque (Narvkg) Muscle architecture All fibres size (µm) Type I fibres size (µm) Type I fibres percentage (%) Type IIa fibres size (µm) Type IIa fibres size (µm)	1 6.0 ± 4.9 (p < 0.05)  NS  1 3.6% (p < 0.0001)  1 7.2% (N.5)  1 2.2% (p < 0.0001)  1 8.9% (N.5)	N/A

 Table 3. Cont.

First Author, Year of Publication	Country	Participant Group (n); Sex (n, %)	$\mathbf{Age} \pm \mathbf{SD}$ or $\pm \mathbf{SEM(*)}$	Study Design	Experimental Group Intervention	Experimental Duration and Frequency, Dosage (h)	Attrition (Reasons)	Outcome Measures	Δ Muscle Remodelling Post-Training (within Group)	Δ Muscle Remodelling Post-Training (between Groups
		Exercise (22); Female (22, 100%)	74.5 ± 0.6 *		RET: it involved 2 supervised and 3 home-based sessions. Progressive intensity of the	12 weeks (5x/week) Dosage = 60		Muscle strength/ capacity Grip strength (kg)	Exercise: † 27.0% (p < 0.001)	p < 0.001
		Exercise (22), 1 etiale (22, 100 %)	74.0 1 0.0		intervention.			Knee extensor strength 60°/s (N)	Exercise: † $42.1\%$ (p < $0.001$ )	p = 0.019
								Knee flexor strength (N)	Exercise: ↓ 1.5% (NS)	p = 0.002
Kim et al., 2015 [44]	Korea	Control (8); Female (8, 100%)	76.05 ± 2.0 *	RCT	Maintenance of normal physical activities and performance of one		<sup>3</sup> Ten participants did not complete the intervention.	Knee extensor strength $180^{\circ}/s$ (N)	Exercise: † 33.7% (NS)	NS
					hour stretching once a week			Knee flexor strength $(N)$	Exercise: $\downarrow$ 19.4% ( $p < 0.001$ )	p = 0.028
								Body composition Waist-hip ratio (WHR)	Exercise: ↓ 1.2% (NS)	N/A
								Arm circumference (cm)	Exercise: ↓ 5.1% (NS)	N/A
								Thigh circumference (cm)	Exercise: ↓ 1.3% (NS)	N/A
Makhnovskii et al., 2020 [30]	Russia	Exercise (7); Male (7, 100%)	22.5 ± 1.5 *	Pre–post study	AET: participants alternated continuous (intensity at 70% LT <sub>4</sub> ) and intermittent exercise ((3 min, 50% LT <sub>4</sub> + 2 min, 85% LT <sub>4</sub> x12)) on different days.	5 weeks (7x/week) Dosage = 35	None	N/A	N/A	N/A
Nishida et al., 2010 [31]	Japan	Exercise (6); Male (6, 100%)	19–32	Pre–post study	Supervised AET: participants performed the session for 60 min using an upright cycle ergometer. Training intensity at the LT level.	12 weeks (5x/week) Dosage = 60	None	Body composition Fat percentage (%) Ventilatory changes VO <sub>2max</sub> (mL/kg * min) VO <sub>2</sub> at LT (mL/kg * min) VO <sub>2max</sub> at LT (%)	\$\to\$ 2.2% (NS)  \$\dagger\$ 8.7% (NS)  \$\dagger\$ 62.5% (p < 0.05)  \$\dagger\$ 48.9% (p < 0.05)	N/A

 Table 3. Cont.

First Author, Year of Publication	Country	Participant Group (n); Sex (n, %)	$\mathbf{Age} \pm \mathbf{SD}$ or $\pm \mathbf{SEM(*)}$	Study Design	Experimental Group Intervention	Experimental Duration and Frequency, Dosage (h)	Attrition (Reasons)	Outcome Measures	Δ Muscle Remodelling Post-Training (within Group)	Δ Muscle Remodelling Post-Training (between Groups)
Norheim et al., 2011 [32]	Norway	Exercise (13); Male (13, 100%)	26.8 (19–35)	Sub-cohort of pre–post study	RET: it involved 1-3 sets of leg press, leg extension, leg curl, seated chest press, seated rowing, latissimus dorsi pull-down, biceps curl, and shoulder press.	11 weeks (3x/week) Dosage = N/A	None	N/A	N/A	N/A
Norheim et al., 2014 [33]	Norway	Exercise (26); Male (26, 100%), Normal glucose group (13), Pre-diabetes group (13)	$51.2 \pm 6.6$	Pre–post study	Supervised CT: it involved 2 interval bicycle sessions and 2 whole body strength-training sessions per week. Each session lasted 1 h.	12 weeks (4x/week) Dosage = 48	None	N/A	N/A	N/A
Radom-Aizak et al., 2005 [35]	Israel	Exercise (6); Male (6, 100%)	68.0 ± 2.7 *	Pre–post study	AET: participants performed 45 min sessions (from the 3rd-12th week) on a cycle ergometer at 80% of the predetermined HR <sub>max</sub> .	12 weeks (3x/week) Dosage = 27	None	Ventilatory changes VO <sub>2max</sub> (L/min) Anaerobic threshold (%)	$\uparrow$ 17.8% ( $p = 0.009$ ) $\uparrow$ 21% ( $p = 0.008$ )	N/A
Raue et al., 2012 [36]	USA	Young (16); Male (8, 50%), Female (8, 50%) Older (12); Male (6, 50%), Female (6, 50%)	24±4 84±3	Pre-post study	RET: it involved 3 sets of 10 bilateral knee extensions (70–75% of 1 RM).	12 weeks (3x/week) Dosage = N/A	None	Muscle strength/ capacity Leg extension strength (kg)  Muscle architecture Thigh muscle CSA (cm²)	† 5.7–† 41.3 kg ↓ 1.2–† 10.4 cm²	N/A
Riedl et al., 2010 [37]	Japan	Exercise (7); Male (7, 100%)	$64\pm2.6$	Pre-post study	Supervised AET:     participants     performed     sessions of 60 min     on a cycle     ergometer.     Training intensity     at the LT level	6 weeks (5x/week) Dosage = 30	None	Body composition Fat percentage (%) Ventilatory changes VO <sub>2</sub> at LT (%) VO <sub>2</sub> max (mL/FFM kg/min)	$\downarrow$ 9.9% ( $p$ < 0.05) $\uparrow$ 8.3% ( $p$ < 0.05) $\uparrow$ 7.3% ( $p$ < 0.05)	N/A

 Table 3. Cont.

First Author, Year of Publication	Country	Participant Group (n); Sex (n, %)	$\begin{aligned} & \textbf{Age} \pm \textbf{SD} \\ & \textbf{or} \pm \textbf{SEM(*)} \end{aligned}$	Study Design	Experimental Group Intervention	Experimental Duration and Frequency, Dosage (h)	Attrition (Reasons)	Outcome Measures	Δ Muscle Remodelling Post-Training (within Group)	Δ Muscle Remodelling Post-Training (between Groups)
		Young HIIT exercise (10); Male,	25.4±4.3					Young HIIT		Absolute VO <sub>2mas</sub> (mL/min) in young: † following HIIT (p < 0.0001) > † following RET (p < 0.048) and CT (p = 0.0001)
		Female			HIIT: participants performed 3 sessions per week of cycling (4 × 4			Ventilatory changes	† (p < 0.001)	
		Older HIIT exercise (8); Male,	70.7 ± 4.6		min at >90% of VO <sub>tmax</sub> separated by 3 min of pedalling at no load) and 2 sessions per week of treadmill	HIIT: 12 weeks (5x/week) Dosage = 34.8		VO <sub>tmax</sub> (mL/kg BW/min)  Body composition  FFM (kg)	† (p < 0.05)	Absolute VO <sub>2max</sub> (mL/min) in
		Female			walking (45 min at 70% of VO <sub>2max</sub> ).			Muscle strength/ capacity		Absolute VO <sub>max</sub> (mL/mm) in older: $\uparrow$ following HIIT ( $p < 0.0091$ ) and CT ( $p = 0.0096$ ) > $\uparrow$ following RET (ns)
		Young RET (10); Male, Female	23.7±3.5					Maximal leg strength (1 RM) leg press (AU/kg Leg FFM)	† (NS)	
Robinson et al., 2017 [38]		Older RET (8); Female	70.3±3.9		RET: participants performed 2 sessions of lower and upper body exercises (4 sets of 8-12 repetitions), 2 days each	RET: 12 weeks (5x/week) Dosage = N/A		<u>Olåer HIIT</u> Ventilatory changes		Relative VO <sub>bess</sub> (mL/min) in young: ↑ ~28% following HIIT (p <0.0001) > ↑ ~17% following CT
2017 [36]		Young Combined exercise (8); Male, Fernale	26.3 ± 2.7		per week.			VO <sub>zmax</sub> (mL/kg BW/min)	† (p < 0.01)	(p < 0.0001) > RET (ns)
								Body composition FFM (kg)	† (p < 0.05)	
		Older Combined exercise (7); Male, Female	68.6 ± 3.4		CT after a 3 months SED: Following SED, participants underwent metabolic studies and			Muscle strength/ capacity		Relative VO <sub>Inse</sub> (mL/min) in
					performed CT of 5 days per week cycling (30 min at 70% VO <sub>tmax</sub> ) and 4 days per week weightlifting with fewer repetitions than RET.	Combined:12 weeks (9x/week Dosage > 30	)	Maximal leg strength (1 RM) leg press) (AU/kg Leg FFM	† (NS)	older: † ~21% following CT (p < 0.0001) > † ~17% following HIIT (p < 0.0001) > RET (ns)
	USA			Pre-post study			Five young and three older participants did not complete the intervention. There was no information on number of males	Ventilatory changes VO2max (mL/kg	† (NS)	
							and females completing the study	y BW/min) Body composition FFM (kg)	† 4% (p < 0.0001)	Leg strength: † Following RET and CT > HIIT (NS)

 Table 3. Cont.

First Author, Year of Publication	Country	Participant Group (n); Sex (n, %)	$egin{aligned} \mathbf{Age} \pm \mathbf{SD} \ \mathbf{or} \pm \mathbf{SEM(*)} \end{aligned}$	Study Design	Experimental Group Intervention	Experimental Duration and Frequency, Dosage (h)	Attrition (Reasons)	Outcome Measures	Δ Muscle Remodelling Post-Training (within Group)	Δ Muscle Remodelling Post-Training (between Groups)
						<u> </u>		Muscle strength/ Maximal leg strength (1 RM) leg press (AU/kg Leg FFM)	† (p < 0.05) †	· · · · · · · · · · · · · · · · · · ·
								Older RET Ventilatory changes VO <sub>max</sub> (mL/kg BW/min)	† (NS)	
								Body composition FFM (kg) Muscle strength/ capacity	† (p < 0.01)	
								Maximal leg strength (1 RM) leg press (AU/kg Leg FFM)	† (p < 0.05)	
								<u>Young CT</u> Ventilatory changes  VO <sub>zmax</sub> (mL/kg BW/min)	† (p < 0.001)	
								Body composition FFM (kg) Muscle strength/ capacity	1 (p < 0.05)	
								Maximal leg strength (1 RM) leg press (AU/kg Leg FFM)	† (p < 0.05)	
								Older CT Ventilatory changes VO <sub>2max</sub> (mL/kg BW/min)	† (p < 0.01)	
								Body composition FFM (kg) Muscle strength/ capacity	† (p < 0.05)	
								Maximal leg strength (1 RM) leg press (AU/kg Leg FFM)	† (p < 0.05)	
Timmons et al., 2010 [39]	Sweden, Denmark, Uk	X, USA Exercise (24); Male (24, 100%)	23	Pre-post study	Supervised AET: participants performed 45 min cycling sessions. Training intensity customized to 70% of the pretraining VO <sub>max</sub> .	6 weeks (±x/week) Dosage = 18	None	Ventilatory changes VO2 max (L/min) Submax RER (ratio)	† 14% (N/A) † 10% (N/A)	N/A

Table 3. Cont.

First Author, Year of Publication	Country	Participant Group (n); Sex (n, %)	$\mathbf{Age} \pm \mathbf{SD}$ or $\pm \mathbf{SEM(*)}$	Study Design	Experimental Group Intervention	Experimental Duration and Frequency, Dosage (h)	Attrition (Reasons)	Outcome Measures	Δ Muscle Remodelling Post-Training (within Group)	Δ Muscle Remodelling Post-Training (between Groups)
					AET: participants performed 30 min sessions on a cycle ergometer			Muscle architecture  Muscle fibre area (µm²)	† 8.3% (NS)	
					at a heart rate corresponding to 65% of Pmax. Training intensity	6 weeks (5x/week) Dosage = 15		Biopsy myofibrils (%)	↓ 4.0% (p < 0.05)	
					maintained at ≈90% of maximal heart rate			Capillary-to-fibre ratio (ALL)	† 12.1% (p < 0.05)	
Valdivierso et al., 2017 [40]	Switzerland	Exercise (61); Male (61, 100%), A/A alleles (12), A/T alleles (38), T/T alleles (11)	29.5 ± 9.3	Pre-post study	reattrate		None	Capillary-to-fibre ratio:  A/A genotype  A/T genotype  T/T genotype  Capillary density (mm <sup>-2</sup> )	† 25.0% (NS) † 12.6% (p < 0.05) † 12.5% (NS) † 5.5% (p < 0.05)	A/A vs. T/T ( $p$ < 0.05) A allele carriers vs. T/T ( $p$ < 0.05)
								Ventilatory changes		
								VO:max (mL/kg * min)	† 8.5% (p < 0.05)	
								${\tt Pmax} \ ({\tt ergospirometry}) \ ({\tt W})$	† 12.7% (p < 0.05)	
Walton et al., 2019 [41]	USA	Exercise (20); Male (4, 25%), Female (16, 75%)	49.8 ± 2.3 *	Pre–post study	AET: participants performed 45 min sessions using a stationary cycle ergometer (at a target intensity corresponding to $65\%$ of $VO_{2max}$ and $\approx 75-80\%$ of maximum heart rate)	12 weeks (3x/week) Dosage = 27	None	N/A	N/A	N/A
Alghadir et al., 2016 [42]	Saudi Arabia	Exercise (25); Male with T2D (25, 100%)	48.8 ± 14.6	RCT	Supervised AET: 50 min in intensity defined by heart rate (THR max; 60–70%)	12 weeks (3x/week) Dosage = 30	None	N/A	N/A	N/A
		Control (25); Male (25, 100%)	$48.7 \pm 3.4$		Sedentary lifestyle					
Olstad et al., 2020	Nama	Exercise healthy (18); Female (18, 100%)	73.9 ± 5.7	Burnata 1	Supervised heavy-load RET: it involved all major muscle groups.	13 weeks (3x/week)	<sup>2</sup> One participant did not complet	Muscle strength/ capacity Relative strength	Healthy: † 32 ± 16%	N/A
[34]	Norway	Exercise osteoporotic (17); Female (17, 100%)	78.0 ± 6.2	Pre-post study	Gradual progression on the training loads was applied. Each session lasted ≈60 min.	Dosage = 39	the study		Osteoporotic: † 31 ± 19%	IV/A

The last two entries are from clinical populations. Data are presented as mean  $\pm$  SD or  $\pm$  SEM (\*); number (n); hours (h); randomised controlled trial (RCT); resistance exercise training (RET); combined training (CT); aerobic exercise training (AET); high intensity interval training (HIIT); sedentary period (SED); electrical stimulation (ES); decrease ( $\downarrow$ ); not significant (NS); not available (N/A); repetition maximum (RM); lean body mass (LBM); cross sectional area (CSA); increase ( $\uparrow$ ); maximum training heart rate (max THR); maximal aerobic capacity (VO<sub>2max</sub>); maximal accumulated oxygen deficit (MAOD); voluntary repetition maximum (VRM); submaximal exercise respiratory exchange ratio (Submax RER); lactate threshold (LT); lactate threshold at 4 mmol/L (LT<sub>4</sub>); body weight (BW); fat free mass (FFM); absolute units (AU); intravenous failure (IV failure); Type 2 Diabetes (T2D); vastus lateralis (VL); quadriceps femoris (QF). Attrition:  $^1$  A male participant was removed from analysis because of poor sample quality.  $^2$  Dropouts and medical issues kept five older and two young participants out of the final analysis.  $^3$  Ten subjects (four in the exercise group, six in the control group) could not complete the study. Reasons: difficulties of time commitment and loss of motivation.  $^4$  Five young adults dropped out from the study. Reasons: (a) time constraints (n = 2), (b) medical unrelated to the study (n = 1). Three older adults dropped out. Reasons: (a) medical unrelated to the study (n = 1), (b) did not want to perform follow up testing (n = 1), and (c) completed sedentary-only portion (n = 1).  $^5$  A compression fracture in the spine was attained during an accident in the squat exercise. Recovery of the patients was succeeded after 3 months of reduced loading.

# 3.2. Exercise Training Increases the Expression of ECMs Associated with Skeletal Muscle Remodelling

Muscle adaptations were quantified in several studies and are presented in Table 3 as muscle strength, body composition and muscle architecture. The changes in muscle strength and capacity were demonstrated as significant increase in leg and knee extension strength, peak torque and grip strength [26,28,29,34,36,38,42,43]. Body composition with increased body fat free mass (FFM), lean body mass (LBM), and decreased percentage of fat was also observed in participants after various exercise training interventions [26,28,31,37,38,42,43]. Muscle architecture also changed significantly with exercise intervention increasing muscle cross-sectional area, fibre size, capillary-to-fibre ratio [26,28,36,40,42]. The studies analysing muscle remodelling and adaptation demonstrated that the exercise training interventions were adequate and sufficient to promote peripheral skeletal muscle changes in both age groups (Table 3). The phenotypical changes in the muscle were accompanied by widespread increase in the expression of ECMs at mRNA and protein level, as listed in Table 4. Among the 54 ECMs reported at the mRNA level, only glypican 4, chondroadherin and LAMβ3 were recoded to be downregulated in older participants. In addition, decorin was downregulated only in young participants when training duration was 12 weeks, otherwise upregulated in all the other conditions tested. At the protein level, 21 ECMs were significantly upregulated in total muscle tissue after exercise training [25,30,40]; however, dermatopontin, irisin, laminin subunit alpha 4 were significantly reduced. Seven studies provide data on direct association of ECM expression and muscle remodelling, which is represented in Table 4. Our findings demonstrate that exercise training induces muscle remodelling as well as ECM changes at transcription and translation levels.

The duration of exercise training was different among age groups. The exercise duration prescribed to younger participants tended to be less than 9 weeks, whereas for older participants training lasted more than 9 weeks. Figure 2 illustrates the overlap in ECMs transcriptomes categorised as collagens, glycoproteins and proteogycans upregulated in young and old populations, when duration of intervention was less and more than 9 weeks. Similar transcriptomes per ECM category were reported in both age groups independent of training duration. The upregulation of collagens, glycoproteins and proteoglycans ECMs were observed across all types of exercise training interventions. Despite the tendency of prescribing AET and HIIT to young participants, and CT to older age groups, similar ECM transcriptomes were reported in both age groups. When comparing the effect of exercise training modalities, Robinson et al. [38] demonstrated that all types of training including CT, RET and HIIT induced similarly ECM transcriptomes in both age groups. However, COL14 $\alpha$ 1, lumican and elastin were the exceptions. The HIIT training upregulated these transcriptomes only in the older participants.

ECM-related molecules were also reported in some of the studies. As they were not part of the outcome search, they were not analysed in this systematic review, but a list is provided in Supplementary Table S2.

 Table 4. Exercise training changes ECMs at protein and mRNA level and are associated with muscle remodelling outcome.

First Author, Year of Publication	Outcome Measure	Δ ECM Outcome Post Training within Group	Association between ECM and Muscle Remodelling Outcome within the Study
Damas et al., 2018 [24]	mRNA expression Collagens COL3A1 COL4A1 COL5A2 Glycoproteins CTHRC1 LAMB1 THBS4 PXDN	$\uparrow 146\% \ (p < 0.05)$ $\uparrow 112\% \ (p < 0.05)$ $\uparrow 95\% \ (p < 0.05)$ $\uparrow 105\% \ (p < 0.05)$ $\uparrow 79\% \ (p < 0.05)$ $\uparrow 144\% \ (p < 0.05)$ $\uparrow 81\% \ (p < 0.05)$	N/A
	Protein expression Glycoproteins Agrin	Slow fibres: $\uparrow$ 147% (NS) Fast fibres: $\uparrow$ 460% ( $p$ < 0.001) Whole muscle: $\uparrow$ 130% (NS)	
	Thrombospondin 4	Slow fibres: $\uparrow 240\%$ (NS) Fast fibres: $\uparrow 360\%$ ( $p = 0.015$ )	
	Peroxidasin	Whole muscle: N/A Slow fibres: $\uparrow$ 320% ( $p$ = 0.0017) Fast fibres: $\uparrow$ 300% (NS) Whole muscle: $\uparrow$ 360% ( $p$ = 0.0018)	
	Dermatopontin	Slow fibres: $\downarrow$ 70% (NS) Fast fibres: $\downarrow$ 85% (NS) Whole muscle: $\downarrow$ 16% ( $p$ = 0.0046)	
	Fibrillin-1	Slow fibres: $\downarrow 100\%$ (NS) Fast fibres: $\downarrow 82\%$ (NS) Whole muscle: $\uparrow 280\%$ ( $p = 0.0063$ )	
	Irisin precursor, fibronectin type III	Slow fibres: † 108% (NS)	
Deshmukh et al., 2021 [25]	IGFN1 (Immunoglobulin-like and fibronectin type III domain containing Laminin subunit alpha-1	Fast fibres: $\downarrow$ 90% (NS) Whole muscle: $\downarrow$ 70% ( $p$ = 0.025) Slow fibres: $\uparrow$ 790% ( $p$ = 0.0028) Fast fibres: $\uparrow$ 560% ( $p$ = 0.011) Whole muscle: $\uparrow$ 225% (NS) Slow fibres: N/A	N/A
	Laminin subunit alpha 4	Fast fibres: N/A Whole muscle: $\uparrow$ 370% ( $p$ = 0.0415) Slow fibres: $\uparrow$ 160% ( $p$ = 0.0119) Fast fibres: $\uparrow$ 143% (NS)	
	Laminin subunit alpha 5	Whole muscle: ↓ 93% (NS) Slow fibres: ↑ 119% (NS) Fast fibres: ↑ 99% (NS)	
	Microfibrillar-associated protein 4	Whole muscle: $\uparrow$ 60% ( $p$ = 0.0431) Slow fibres: $\downarrow$ 90% (NS) Fast fibres: $\downarrow$ 39% ( $p$ = 0.043)	
	Microfibrillar-associated protein 5	Whole muscle: $\uparrow$ 137% (NS) Slow fibres: $\uparrow$ 440% ( $p$ = 0.0197) Fast fibres: $\uparrow$ 62% (NS)	
	Picachurin (EGFLAM)	Whole muscle: $\uparrow$ 162% (NS) Slow fibres: $\uparrow$ 300% ( $p$ = 0.0197) Fast fibres: $\uparrow$ 510% ( $p$ < 0.001) Whole muscle: $\uparrow$ 330% ( $p$ = 0.0008)	
	Circulating markers (serum)	· · · ·	P3NP vs. LBM (r = 0.422,
	C-terminal agrin fragment (CAF)	Exercise: † 10.4% (NS)	p = 0.045)
Fragala et al., 2014 [43]		Control: ↑ 0.3% (NS)	CAF vs. VL CSA ( $r = 0.542$ , $p = 0.008$ )
5	N-terminal peptide of procollagen type III (P3NP)	Exercise: ↑7.9% (NS) Control: ↑1.9% (NS)	P3NP vs. muscle strength/quali (NS)
		Control.   1.970 (190)	CAF vs. muscle strength/quali (NS)

 Table 4. Cont.

First Author, Year of Publication	Outcome Measure	Δ ECM Outcome Post Training within Group	Association between ECM and Muscle Remodelling Outcome within the Study
	mRNA expression		
	Collagens		
	COL1A1	$\uparrow 140\% \ (p < 0.001)$	
	COL1A2	$\uparrow 80\% \ (p < 0.001)$	
	COL3A1	$\uparrow 140\% \ (p < 0.001)$	
	COL4A1	$\uparrow 140\% \ (p < 0.001)$	
	COL4A2	$\uparrow 120\% \ (p < 0.001)$	
	COL5A1	$\uparrow 50\% \ (p < 0.001)$	
	COL5A2	$\uparrow$ 60% ( $p$ < 0.001)	
	COL6A6	$\uparrow 100\% \ (p < 0.001)$	
	COL14A1	$\uparrow$ 80% ( <i>p</i> < 0.001)	
	COL15A1	$\uparrow 50\% \ (p < 0.001)$	
	COL18A1	$\uparrow 50\% \ (p < 0.001)$	
	Proteoglycans	1 000/ ( 0 001)	
	ASPN	$\uparrow 80\% \ (p < 0.001)$	
	BGN	$\uparrow 110\% \ (p < 0.001)$	
	HSPG2	$\uparrow 50\% \ (p < 0.001)$	
	OGN	$\uparrow 110\% \ (p < 0.001)$	
Hjorth et al., 2015 [26]	OMD ECM2	$\uparrow 80\% \ (p < 0.001)$	NT / A
Hjortii et al., 2013 [26]	LUM	$\uparrow 60\% \ (p < 0.001)$	N/A
	GPC4	$\uparrow 50\% \ (p < 0.001)$ $\downarrow \text{N/A} \ (p < 0.001)$	
	CHAD	$\downarrow 52\% \ (p < 0.001)$	
	CSPG4	$\uparrow 52\% (p < 0.001)$ $\uparrow 50\% (p < 0.001)$	
	Glycoproteins	30 / 0 (β < 0.001)	
	AGRN	$\uparrow$ 60% ( $p$ < 0.001)	
	LAMA4	$\uparrow 70\% \ (p < 0.001)$	
	LAMB1	70 % (p < 0.001	
	LAMB3	$\downarrow 56\% \ (p < 0.001)$	
	LAMC3	$\uparrow 70\% \ (p < 0.001)$	
	THBS1	$\uparrow$ 60% ( $p$ < 0.001)	
	THBS4	$\uparrow$ 220% ( $p$ < 0.001)	
	NID1	$\uparrow$ 60% (p < 0.001)	
	NID2	$\uparrow$ 70% ( $p$ < 0.001)	
	PXDN	$\uparrow$ 200% ( $p$ < 0.001)	
	ELN	$\uparrow 50\% \ (p < 0.001)$	
	EMILIN3	$\uparrow$ 60% ( $p$ < 0.001)	
	SPARC	$\uparrow 80\% \ (p < 0.001)$	
	CTHRC1	$\uparrow 70\% \ (p < 0.001)$	
	mRNA expression Proteoglycans		$\Delta$ Decorin expression vs. $\Delta$ Le
Kanzleiter et al., 2014 [27]	0.0	TT 1d 4 / 0.050	press strength (kg) ( $r = 0.56$ ,
	DCN	Healthy: $\uparrow (p < 0.05)$	p = 0.047)
		Pre-diabetes: $\downarrow$ (NS)	,
	mRNA expression		<del></del>
	Collagens		
Karlsen et al., 2020 [28]	COL1A1	Young: (NS)	
		Older: $\uparrow$ (values not reported) $(p < 0.05)$	
	mRNA expression	4/	
	Collagens		
Kern et al., 2014 [29]	COL1	$\uparrow (p < 0.005)$	
,	COL3	$\uparrow (p < 0.005)$	
	COL6	$\uparrow (p < 0.005)$	
	Circulating markers (serum)		
	Irisin	Exercise: $\uparrow$ 22.5% ( $p < 0.05$ )	Irisin vs. grip strength
Kim et al., 2015 [44]		Control: NS	(r = 0.526, p = 0.002)
1 mil et al., 2010 [11]			
			Irisin vs. leg strength

 Table 4. Cont.

mRNA expression Collagens COL1A1 COL1A2 COL3A1 COL4A2 COL6A1 COL6A2 COL6A3 COL15A1 Proteoglycans ASPN BGN HSPG2 OGN LUM DCN PRELP Glycoproteins LAMB1 LAMC1 Protein expression Collagens Collagen Type I Alpha 1 Chain collagen Type III Alpha 1 Chain collagen Type III Alpha 1 Chain collagen Type VI Alpha 1 Chain	$\uparrow 1060\% (p < 0.05)$ $\uparrow 440\% (p < 0.05)$ $\uparrow 656\% (p < 0.05)$ $\uparrow 439\% (p < 0.05)$ $\uparrow 196\% (p < 0.05)$ $\uparrow 232\% (p < 0.05)$ $\uparrow 273\% (p < 0.05)$ $\uparrow 608\% (p < 0.05)$ $\uparrow 271\% (p < 0.05)$ $\uparrow 435\% (p < 0.05)$ $\uparrow 441\% (p < 0.05)$ $\uparrow 447\% (p < 0.05)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow 175\% (p < 0.05)$ $\uparrow 175\% (p < 0.05)$ $\uparrow 175\% (p < 0.05)$ $\uparrow 174\% (p < 0.05)$ $\uparrow 175\% (p < 0.05)$ $\uparrow 174\% (p < 0.05)$	N/A
Collagens COL1A1 COL1A2 COL3A1 COL4A2 COL6A1 COL6A2 COL6A3 COL14A1 COL15A1 Proteoglycans ASPN BGN HSPG2 OGN LUM DCN PRELP Glycoproteins LAMB1 LAMC1 Protein expression Collagen Type I Alpha 1 Chain follagen Type III Alpha 1 Chain follagen Type VI Alpha 1 Chain follagen Type VI Alpha 1 Chain	$\uparrow 440\% (p < 0.05)$ $\uparrow 656\% (p < 0.05)$ $\uparrow 439\% (p < 0.05)$ $\uparrow 196\% (p < 0.05)$ $\uparrow 232\% (p < 0.05)$ $\uparrow 273\% (p < 0.05)$ $\uparrow 608\% (p < 0.05)$ $\uparrow 271\% (p < 0.05)$ $\uparrow 435\% (p < 0.05)$ $\uparrow 441\% (p < 0.05)$ $\uparrow 447\% (p < 0.05)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow 171\% (p < 0.05)$ $\uparrow 173\% (p < 0.05)$ $\uparrow 201\% (p < 0.05)$	N/A
COLÍA1 COL1A2 COL3A1 COL4A2 COL6A1 COL6A2 COL6A3 COL14A1 COL15A1 Proteoglycans ASPN BGN HSPG2 OGN LUM DCN PRELP Glycoproteins LAMB1 LAMC1 Protein expression Collagens Type I Alpha 1 Chain follagen Type III Alpha 1 Chain llagen Type VI Alpha 1 Chain	$\uparrow 440\% (p < 0.05)$ $\uparrow 656\% (p < 0.05)$ $\uparrow 439\% (p < 0.05)$ $\uparrow 196\% (p < 0.05)$ $\uparrow 232\% (p < 0.05)$ $\uparrow 273\% (p < 0.05)$ $\uparrow 608\% (p < 0.05)$ $\uparrow 271\% (p < 0.05)$ $\uparrow 435\% (p < 0.05)$ $\uparrow 441\% (p < 0.05)$ $\uparrow 447\% (p < 0.05)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow 171\% (p < 0.05)$ $\uparrow 173\% (p < 0.05)$ $\uparrow 201\% (p < 0.05)$	N/A
COL3A1 COL4A2 COL6A1 COL6A2 COL6A3 COL14A1 COL15A1 Proteoglycans ASPN BGN HSPG2 OGN LUM DCN PRELP Glycoproteins LAMB1 LAMC1 Protein expression Collagens Type I Alpha 1 Chain collagen Type III Alpha 1 Chain	$\uparrow 656\% (p < 0.05)$ $\uparrow 439\% (p < 0.05)$ $\uparrow 196\% (p < 0.05)$ $\uparrow 232\% (p < 0.05)$ $\uparrow 273\% (p < 0.05)$ $\uparrow 608\% (p < 0.05)$ $\uparrow 271\% (p < 0.05)$ $\uparrow 359\% (p < 0.05)$ $\uparrow 435\% (p < 0.05)$ $\uparrow 204\% (p < 0.05)$ $\uparrow 421\% (p < 0.05)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow 175\% (p < 0.05)$ $\uparrow 173\% (p < 0.05)$ $\uparrow 173\% (p < 0.05)$ $\uparrow 173\% (p < 0.05)$ $\uparrow 201\% (p < 0.05)$	N/A
COL3A1 COL4A2 COL6A1 COL6A2 COL6A3 COL14A1 COL15A1 Proteoglycans ASPN BGN HSPG2 OGN LUM DCN PRELP Glycoproteins LAMB1 LAMC1 Protein expression Collagens Type I Alpha 1 Chain collagen Type III Alpha 1 Chain	$\uparrow 656\% (p < 0.05)$ $\uparrow 439\% (p < 0.05)$ $\uparrow 196\% (p < 0.05)$ $\uparrow 232\% (p < 0.05)$ $\uparrow 273\% (p < 0.05)$ $\uparrow 608\% (p < 0.05)$ $\uparrow 271\% (p < 0.05)$ $\uparrow 359\% (p < 0.05)$ $\uparrow 435\% (p < 0.05)$ $\uparrow 204\% (p < 0.05)$ $\uparrow 421\% (p < 0.05)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow 175\% (p < 0.05)$ $\uparrow 173\% (p < 0.05)$ $\uparrow 173\% (p < 0.05)$ $\uparrow 173\% (p < 0.05)$ $\uparrow 201\% (p < 0.05)$	N/A
COL4A2 COL6A1 COL6A2 COL6A3 COL14A1 COL15A1 Proteoglycans ASPN BGN HSPG2 OGN LUM DCN PRELP Glycoproteins LAMB1 LAMC1 Protein expression Collagen Type I Alpha 1 Chain collagen Type III Alpha 1 Chain	$\uparrow 439\% (p < 0.05)$ $\uparrow 196\% (p < 0.05)$ $\uparrow 232\% (p < 0.05)$ $\uparrow 273\% (p < 0.05)$ $\uparrow 608\% (p < 0.05)$ $\uparrow 271\% (p < 0.05)$ $\uparrow 359\% (p < 0.05)$ $\uparrow 435\% (p < 0.05)$ $\uparrow 421\% (p < 0.05)$ $\uparrow 447\% (p < 0.05)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow 175\% (p < 0.05)$ $\uparrow 173\% (p < 0.05)$ $\uparrow 173\% (p < 0.05)$ $\uparrow 221\% (p < 0.05)$	N/A
COL6A2 COL6A3 COL14A1 COL15A1 Proteoglycans ASPN BGN HSPG2 OGN LUM DCN PRELP Glycoproteins LAMB1 LAMC1 Protein expression Collagens Gollagen Type I Alpha 1 Chain collagen Type III Alpha 1 Chain llagen Type XIV Alpha 1 Chain	$\uparrow 196\% (p < 0.05)$ $\uparrow 232\% (p < 0.05)$ $\uparrow 273\% (p < 0.05)$ $\uparrow 608\% (p < 0.05)$ $\uparrow 608\% (p < 0.05)$ $\uparrow 271\% (p < 0.05)$ $\uparrow 359\% (p < 0.05)$ $\uparrow 435\% (p < 0.05)$ $\uparrow 204\% (p < 0.05)$ $\uparrow 421\% (p < 0.05)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow 175\% (p < 0.05)$ $\uparrow 173\% (p < 0.05)$ $\uparrow 173\% (p < 0.05)$ $\uparrow 221\% (p < 0.05)$	N/A
COL6A2 COL6A3 COL14A1 COL15A1 Proteoglycans ASPN BGN HSPG2 OGN LUM DCN PRELP Glycoproteins LAMB1 LAMC1 Protein expression Collagens Gollagen Type I Alpha 1 Chain collagen Type III Alpha 1 Chain llagen Type XIV Alpha 1 Chain	$\uparrow 232\% (p < 0.05)$ $\uparrow 273\% (p < 0.05)$ $\uparrow 608\% (p < 0.05)$ $\uparrow 271\% (p < 0.05)$ $\uparrow 359\% (p < 0.05)$ $\uparrow 435\% (p < 0.05)$ $\uparrow 421\% (p < 0.05)$ $\uparrow 421\% (p < 0.05)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow 175\% (p < 0.05)$ $\uparrow 173\% (p < 0.05)$ $\uparrow 173\% (p < 0.05)$ $\uparrow 221\% (p < 0.05)$	N/A
COL6A3 COL14A1 COL15A1 Proteoglycans ASPN BGN HSPG2 OGN LUM DCN PRELP Glycoproteins LAMB1 LAMC1 Protein expression Collagens Type I Alpha 1 Chain follagen Type III Alpha 1 Chain llagen Type XIV Alpha 1 Chain	$\uparrow 273\% (p < 0.05)$ $\uparrow 608\% (p < 0.05)$ $\uparrow 271\% (p < 0.05)$ $\uparrow 359\% (p < 0.05)$ $\uparrow 435\% (p < 0.05)$ $\uparrow 204\% (p < 0.05)$ $\uparrow 421\% (p < 0.05)$ $\uparrow 447\% (p < 0.05)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow 175\% (p < 0.05)$ $\uparrow 173\% (p < 0.05)$ $\uparrow 221\% (p < 0.05)$	N/A
COL14A1 COL15A1 Proteoglycans ASPN BGN HSPG2 OGN LUM DCN PRELP Glycoproteins LAMB1 LAMC1 Protein expression Collagens Type I Alpha 1 Chain follagen Type III Alpha 1 Chain llagen Type XIV Alpha 1 Chain	$\uparrow 608\% (p < 0.05)$ $\uparrow 271\% (p < 0.05)$ $\uparrow 359\% (p < 0.05)$ $\uparrow 435\% (p < 0.05)$ $\uparrow 204\% (p < 0.05)$ $\uparrow 421\% (p < 0.05)$ $\uparrow 447\% (p < 0.05)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow 175\% (p < 0.05)$ $\uparrow 171\% (p < 0.05)$ $\uparrow 173\% (p < 0.05)$ $\uparrow 221\% (p < 0.05)$	N/A
COL15A1  Proteoglycans  ASPN  BGN  HSPG2  OGN  LUM  DCN  PRELP  Glycoproteins  LAMB1  LAMC1  Protein expression  Collagens  Collagen Type I Alpha 1 Chain  ollagen Type IXI Alpha 1 Chain  llagen Type XIV Alpha 1 Chain  llagen Type XIV Alpha 1 Chain	$\uparrow 271\% \ (p < 0.05)$ $\uparrow 359\% \ (p < 0.05)$ $\uparrow 435\% \ (p < 0.05)$ $\uparrow 204\% \ (p < 0.05)$ $\uparrow 421\% \ (p < 0.05)$ $\uparrow 447\% \ (p < 0.05)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow 175\% \ (p < 0.05)$ $\uparrow 173\% \ (p < 0.05)$ $\uparrow 221\% \ (p < 0.05)$	N/A
Proteoglycans ASPN BGN HSPG2 OGN LUM DCN PRELP Glycoproteins LAMB1 LAMC1 Protein expression Collagens Type I Alpha 1 Chain follagen Type III Alpha 1 Chain llagen Type XIV Alpha 1 Chain	$\uparrow$ 359% $(p < 0.05)$ $\uparrow$ 435% $(p < 0.05)$ $\uparrow$ 204% $(p < 0.05)$ $\uparrow$ 421% $(p < 0.05)$ $\uparrow$ 447% $(p < 0.05)$ $\uparrow$ (NS) $\uparrow$ (NS) $\uparrow$ (NS) $\uparrow$ 175% $(p < 0.05)$ $\uparrow$ 171% $(p < 0.05)$ $\uparrow$ 173% $(p < 0.05)$ $\uparrow$ 221% $(p < 0.05)$	N/A
ASPN BGN HSPG2 OGN LUM DCN PRELP Glycoproteins LAMB1 LAMC1 Protein expression Collagens Tollagen Type I Alpha 1 Chain follagen Type III Alpha 1 Chain llagen Type XIV Alpha 1 Chain	$\uparrow 435\% (p < 0.05)$ $\uparrow 204\% (p < 0.05)$ $\uparrow 421\% (p < 0.05)$ $\uparrow 447\% (p < 0.05)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow 175\% (p < 0.05)$ $\uparrow 173\% (p < 0.05)$ $\uparrow 221\% (p < 0.05)$	N/A
HSPG2 OGN LUM DCN PRELP Glycoproteins LAMB1 LAMC1 Protein expression Collagens Type I Alpha 1 Chain collagen Type III Alpha 1 Chain llagen Type XIV Alpha 1 Chain	$\uparrow 435\% (p < 0.05)$ $\uparrow 204\% (p < 0.05)$ $\uparrow 421\% (p < 0.05)$ $\uparrow 447\% (p < 0.05)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow 175\% (p < 0.05)$ $\uparrow 173\% (p < 0.05)$ $\uparrow 221\% (p < 0.05)$	N/A
HSPG2 OGN LUM DCN PRELP Glycoproteins LAMB1 LAMC1 Protein expression Collagens Type I Alpha 1 Chain collagen Type III Alpha 1 Chain llagen Type XIV Alpha 1 Chain	$ \uparrow 204\% \ (p < 0.05) $ $ \uparrow 421\% \ (p < 0.05) $ $ \uparrow 447\% \ (p < 0.05) $ $ \uparrow (NS) $ $ \uparrow (NS) $ $ \uparrow (NS) $ $ \uparrow 175\% \ (p < 0.05) $ $ \uparrow 171\% \ (p < 0.05) $ $ \uparrow 173\% \ (p < 0.05) $ $ \uparrow 221\% \ (p < 0.05) $	N/A
OGN LUM DCN PRELP Glycoproteins LAMB1 LAMC1 Protein expression Collagens Type I Alpha 1 Chain collagen Type II Alpha 1 Chain collagen Type III Alpha 1 Chain collagen Type VI Alpha 1 Chain	$\uparrow 421\% (p < 0.05)$ $\uparrow 447\% (p < 0.05)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow 326\% (p < 0.05)$ $\uparrow 175\% (p < 0.05)$ $\uparrow 171\% (p < 0.05)$ $\uparrow 173\% (p < 0.05)$ $\uparrow 221\% (p < 0.05)$	N/A
LUM DCN PRELP Glycoproteins LAMB1 LAMC1 Protein expression Collagens Tollagen Type I Alpha 1 Chain collagen Type III Alpha 1 Chain bllagen Type XIV Alpha 1 Chain collagen Type VI Alpha 1 Chain	$\uparrow 447\% (p < 0.05)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow (NS)$ $\uparrow 326\% (p < 0.05)$ $\uparrow 175\% (p < 0.05)$ $\uparrow 171\% (p < 0.05)$ $\uparrow 173\% (p < 0.05)$ $\uparrow 221\% (p < 0.05)$	N/A
DCN PRELP Glycoproteins LAMB1 LAMC1 Protein expression Collagens Collagen Type I Alpha 1 Chain Collagen Type III Alpha 1 Chain Collagen Type III Alpha 1 Chain Collagen Type XIV Alpha 1 Chain Collagen Type VI Alpha 1 Chain Collagen Type VI Alpha 1 Chain	$\uparrow \text{ (NS)} \\ \uparrow \text{ (NS)}$ $\uparrow 326\% \ (p < 0.05)$ $\uparrow 175\% \ (p < 0.05)$ $\uparrow 171\% \ (p < 0.05)$ $\uparrow 173\% \ (p < 0.05)$ $\uparrow 221\% \ (p < 0.05)$	N/A
PRELP Glycoproteins LAMB1 LAMC1 Protein expression Collagens Collagen Type I Alpha 1 Chain Collagen Type III Alpha 1 Chain Collagen Type III Alpha 1 Chain Collagen Type XIV Alpha 1 Chain Collagen Type VI Alpha 1 Chain Collagen Type VI Alpha 1 Chain	$\uparrow \text{ (NS)}$ $\uparrow 326\% \ (p < 0.05)$ $\uparrow 175\% \ (p < 0.05)$ $\uparrow 171\% \ (p < 0.05)$ $\uparrow 173\% \ (p < 0.05)$ $\uparrow 221\% \ (p < 0.05)$	.,,
Glycoproteins LAMB1 LAMC1 Protein expression Collagens Collagen Type I Alpha 1 Chain Collagen Type II Alpha 2 Chain Collagen Type III Alpha 1 Chain Collagen Type XIV Alpha 1 Chain Collagen Type VI Alpha 1 Chain Collagen Type VI Alpha 1 Chain	$\uparrow$ 326% ( $p$ < 0.05) $\uparrow$ 175% ( $p$ < 0.05) $\uparrow$ 171% ( $p$ < 0.05) $\uparrow$ 173% ( $p$ < 0.05) $\uparrow$ 221% ( $p$ < 0.05)	
LAMB1 LAMC1 Protein expression Collagens Collagen Type I Alpha 1 Chain Collagen Type II Alpha 2 Chain Collagen Type III Alpha 1 Chain Collagen Type XIV Alpha 1 Chain Collagen Type VI Alpha 1 Chain Collagen Type VI Alpha 1 Chain	$\uparrow 175\% \ (p < 0.05)$ $\uparrow 171\% \ (p < 0.05)$ $\uparrow 173\% \ (p < 0.05)$ $\uparrow 221\% \ (p < 0.05)$	
LAMC1 Protein expression Collagens Collagen Type I Alpha 1 Chain Collagen Type I Alpha 2 Chain Collagen Type III Alpha 1 Chain Collagen Type XIV Alpha 1 Chain Collagen Type VI Alpha 1 Chain Collagen Type VI Alpha 1 Chain	$\uparrow 175\% \ (p < 0.05)$ $\uparrow 171\% \ (p < 0.05)$ $\uparrow 173\% \ (p < 0.05)$ $\uparrow 221\% \ (p < 0.05)$	
Protein expression Collagens Collagen Type I Alpha 1 Chain Collagen Type I Alpha 2 Chain Collagen Type III Alpha 1 Chain Collagen Type XIV Alpha 1 Chain Collagen Type VI Alpha 1 Chain Collagen Type VI Alpha 1 Chain	$\uparrow$ 171% ( $p < 0.05$ ) $\uparrow$ 173% ( $p < 0.05$ ) $\uparrow$ 221% ( $p < 0.05$ )	
Collagens Collagen Type I Alpha 1 Chain Collagen Type I Alpha 2 Chain Dllagen Type III Alpha 1 Chain Ilagen Type XIV Alpha 1 Chain Dllagen Type VI Alpha 1 Chain	$\uparrow 173\% \ (p < 0.05)$ $\uparrow 221\% \ (p < 0.05)$	
ollagen Type I Alpha 1 Chain follagen Type I Alpha 2 Chain ollagen Type III Alpha 1 Chain Ilagen Type XIV Alpha 1 Chain ollagen Type VI Alpha 1 Chain	$\uparrow 173\% \ (p < 0.05)$ $\uparrow 221\% \ (p < 0.05)$	
ollagen Type I Alpha 2 Chain ollagen Type III Alpha 1 Chain llagen Type XIV Alpha 1 Chain ollagen Type VI Alpha 1 Chain	$\uparrow 173\% \ (p < 0.05)$ $\uparrow 221\% \ (p < 0.05)$	
bllagen Type III Alpha 1 Chain llagen Type XIV Alpha 1 Chain bllagen Type VI Alpha 1 Chain	$\uparrow$ 221% ( $p$ < 0.05)	
llagen Type XIV Alpha 1 Chain ollagen Type VI Alpha 1 Chain		
ollagen Type VI Alpha 1 Chain	10170 (p < 0.00)	
	$\uparrow 124\% \ (p < 0.05)$	
	$\uparrow 121\% \ (p < 0.05)$	
ollagen Type VI Alpha 3 Chain	$\uparrow 124\% \ (p < 0.05)$	
Proteoglycans	12170 (p < 0.00)	
Asporin	$\uparrow 152\% \ (p < 0.05)$	
Lumican	$\uparrow 123\% \ (p < 0.05)$	
rgin (or Proline and arginine rich	, ,	
nd leucine rich repeat protein)	$\uparrow 118\% \ (p < 0.05)$	
1RNA expression (using SAGE)		
Collagens		
COL1A2	$\uparrow 1200\% \ (p < 0.05)$	N/A
Proteoglycan		
DCN	$\downarrow 2100\% \ (p < 0.05)$	
mRNA expression		
Collagens	NA NII A 500 (	
COL1A1	M. VL: $\uparrow 520 \ (p < 0.05)$	
D 4 1	M. TRAP: $\uparrow$ 4340% ( $p$ < 0.05)	
0 0	NA NT	
LUM		
FC) 44		N/A
ECM1	. ,	11/11
at	M. TRAP: $\uparrow$ 190 ( $p < 0.05$ )	
	M M A 200 ( 0.05)	
SPAKC		
F2 14	, ,	
FNI		
mPNA armraccion	111. 1141 · 1 200 (p < 0.00)	
	Healthy: $40\% (n < 0.05)$	
TINDES (IIISIII)		N/A
		IN/A
Circulating markons (comme)	rieaiuty: ↓ (INS)	
Circulating markers (serum)		
Irisin	Pre-diabetes: ↓ (NS)	
		N/A
	Proteoglycans LUM  ECM1  Glycoproteins SPARC  FN1  mRNA expression FNDC5 (Irisin)  Circulating markers (serum)	Proteoglycans         LUM       M. VL: ↑ 250 ( $p < 0.05$ )         M. TRAP: ↑ 430 ( $p < 0.05$ )       M. VL: ↑ 180 ( $p < 0.05$ )         M. VL: ↑ 180 ( $p < 0.05$ )       M. TRAP: ↑ 190 ( $p < 0.05$ )         Glycoproteins       SPARC       M. VL: ↑ 290 ( $p < 0.05$ )         M. TRAP: ↑ 960 ( $p < 0.05$ )       M. VL: ↑ 180 ( $p < 0.05$ )         FN1       M. VL: ↑ 180 ( $p < 0.05$ )         M. TRAP: ↑ 250 ( $p < 0.05$ )       M. TRAP: ↑ 250 ( $p < 0.05$ )         Pre-diabetes: ↑ 100% ( $p < 0.01$ )       Pre-diabetes: ↑ 100% ( $p < 0.01$ )         Circulating markers (serum)       Healthy: ↓ (NS)

 Table 4. Cont.

First Author, Year of Publication	Outcome Measure	Δ ECM Outcome Post Training within Group	Association between ECM and Muscle Remodelling Outcome within the Study
	mRNA expression		Pooled mRNA expression of
	,		$COL4\alpha 2 \text{ vs. } 1\text{-RM } (r = -0.418)$
	Collagens		Pooled mRNA expression of
	COL1A1	Young: N/A	$COL4\alpha3$ vs. 1-RM
			(r = -0.344 - (-0.486))
		Older: ↑ 220–300%	Pooled mRNA expression of
	COL1A2	Young: N/A	COL4 $\alpha$ 4 vs. 1-RM (r = -0.540-(0.623))
		Older: ↑ 150–200%	Pooled mRNA expression of COL4 $\alpha$ 5 vs. 1-RM (r = $-0.547$ )
	COL3A1	Young: N/A	Pooled mRNA expression of COLQ vs. 1-RM (r = 0.652) Pooled mRNA expression of
		Older: ↑ 260–210%	COL27 $\alpha$ 1 vs. 1-RM (r = -0.355-(-0.457))
	COL4A1	Young: † 190–200%	Pooled mRNA expression of COL28 $\alpha$ 1 vs. 1-RM (r = $-0.180$
		Older: N/A	Pooled mRNA expression of CSPG4 vs. 1-RM (r = 0.421) Pooled mRNA expression of
	COL4A2	Young: ↑ 170%	COL4 $\alpha$ 2 vs. CSA (r = -0.405) Pooled mRNA expression of
		Older: ↑ 220%	COL4 $\alpha$ 3 vs. CSA (r = -0.345-(-0.462))
D 1 2012 [0]	COL5A1	Young: N/A	Pooled mRNA expression of COL4 $\alpha$ 4 vs. CSA (r = $-0.461$ -(0.486))
Raue et al., 2012 [36]		Older: ↑ 290%	Pooled mRNA expression of COL4 $\alpha$ 5 vs. CSA (r = $-0.406$ )
	COL5A2	Young: N/A	Pooled mRNA expression of COLQ vs. CSA (r= 0.540) Pooled mRNA expression of
		Older: ↑ 180%	COL27 $\alpha$ 1 vs. CSA (r = $-0.348$ )
	COL5A3	Young: N/A	`
	COL 15 4 1	Older: ↑ 170–180%	
	COL15A1	Young: N/A Older: ↑ 150%	
	Proteoglycans	Older.   13076	
	ASPN	Young: N/A	
	Classical	Older: ↑ 200%	
	Glycoproteins LAMA4	Young: N/A	
	22111111	Older: ↑ 174%	
	LAMB1	Young: N/A	
	NID1	Older: ↑ 165% Young: N/A	
	NIDI	Older: ↑ 160–200%	
	NID2	Young: N/A	
	CDA DC	Older: ↑ 194%	
	SPARC	Young: N/A Older: ↑ 150–160%	
	THBS4	Young: N/A	
		Older: ↑ 168%	
	CTHRC1	Young: N/A Older: ↑ 200%	
Riedl et al., 2010 [37]	Number of tags per 100,000 SAGE tags	23077	
	Collagens		
	COL3A1	↑14	
	COL4A1	<b>†</b> 15	
	Glycoproteins	4.00	
	SPARC	↑ 20	

 Table 4. Cont.

First Author, Year of Publication	Outcome Measure	Δ ECM Outcome Post Training within Group	Association between ECM and Muscle Remodelling Outcome within the Study
	mRNA expression		
	Collagens	LHIE A 2170/ ( < 0.05)	
	COL4A1	HIIT young: $\uparrow$ 217% ( $p \le 0.05$ ) HIIT older: $\uparrow$ 361% ( $p \le 0.05$ )	
		RET young: $\uparrow 267\%$ ( $p \le 0.05$ )	
		RET older: $\uparrow 236\% \ (p \le 0.05)$	
		CT young: $\uparrow 185\% \ (p \le 0.05)$	
	COL4A2	CT older: $\uparrow$ 197% ( $p \le 0.05$ ) HIIT young: $\uparrow$ 188% ( $p \le 0.05$ )	
	COLHAZ	HIIT older: $\uparrow 303\%$ ( $p \le 0.05$ )	
		RET young: $\uparrow$ 219% ( $p \leq 0.05$ )	
		RET older: $\uparrow 202\% \ (p \le 0.05)$	
		CT young: $\uparrow 172\%$ ( $p \le 0.05$ ) CT older: $\uparrow 182\%$ ( $p \le 0.05$ )	
	COL14A1	HIIT young: (NS)	
		HIIT older: $\uparrow 165\%$ ( $p \le 0.05$ )	
		RET young: (NS)	
		RET older: (NS)	
		CT young: (NS)	
	Proteoglycans	CT older: (NS) HIIT young: $\uparrow$ 174% ( $p \le 0.05$ )	
	ASPN	HIIT older: $\uparrow$ 232% ( $p \le 0.05$ )	
		RET young: $\uparrow$ 187% ( $p \le 0.05$ )	
		RET older: $\uparrow 243\% \ (p \le 0.05)$	
		CT young: $\uparrow 158\%$ ( $p \le 0.05$ ) CT older: $\uparrow 177\%$ ( $p \le 0.05$ )	
	LUM	HIIT young: (NS)	
		HIIT older: $\uparrow 156\%$ ( $p \le 0.05$ )	
		RET young: (NS)	
		RET older: (NS) CT young: (NS)	
		CT older: (NS)	
	ECM2	HIIT young: $\uparrow 175\% \ (p \le 0.05)$	
		HIIT older: $\uparrow 180\% \ (p \le 0.05)$	
		RET young: $\uparrow$ 161% ( $p \le 0.05$ ) RET older: $\uparrow$ 173% ( $p \le 0.05$ )	
		CT young: (NS)	
		CT older: (NS)	
	Glycoproteins	LHIT	
Robinson et al., 2017 [38]	LAMB1	HIIT young: $\uparrow$ 171% ( $p \le 0.05$ ) HIIT older: $\uparrow$ 170% ( $p \le 0.05$ )	N/A
		RET young: $\uparrow 154\%$ ( $p \le 0.05$ )	
		RET older: (NS)	
		CT young: (NS) CT older: $\uparrow$ 160% ( $p \le 0.05$ )	
	NID1	HIIT young: $\uparrow 160\% (p \le 0.05)$	
	1,22	HIIT older: $\uparrow$ 205% ( $p \le 0.05$ )	
		RET young: $\uparrow 152\%$ ( $p \le 0.05$ )	
		RET older: $\uparrow 157\%$ ( $p \le 0.05$ ) CT young: $\uparrow 155\%$ ( $p < 0.05$ )	
		CT older: $\uparrow 156\%$ ( $p \le 0.05$ )	
	PXDN	HIIT young: $\uparrow 196\%$ ( $p \le 0.05$ )	
		HIIT older: $\uparrow 266\%$ ( $p \le 0.05$ )	
		RET young: $\uparrow$ 234% ( $p \le 0.05$ ) RET older: $\uparrow$ 209% ( $p \le 0.05$ )	
		CT young: $\uparrow 162\%$ ( $p \le 0.05$ )	
		CT older: $\uparrow 166\% \ (p \le 0.05)$	
	SPARC	HIIT young: $\uparrow 188\% \ (p \le 0.05)$	
		HIIT older: $\uparrow$ 224% ( $p \le 0.05$ ) RET young: $\uparrow$ 170% ( $p \le 0.05$ )	
		RET young.   170% ( $p \le 0.05$ ) RET older: $\uparrow$ 179% ( $p \le 0.05$ )	
		CT young: (NS)	
	TOT A T	CT older: $\uparrow 165\% \ (p \le 0.05)$	
	ELN	HIIT young: (NS)	

 Table 4. Cont.


First Author, Year of Publication	Outcome Measure	Δ ECM Outcome Post Training within Group	Association between ECM and Muscle Remodelling Outcome within the Study
		HIIT older: $\uparrow$ 181% ( $p \le 0.05$ ) RET young: (NS) RET older: (NS) CT young: (NS) CT older: (NS)	
	POSTN	HIIT young: (NS) HIIT older: $\uparrow$ 167% ( $p \le 0.05$ ) RET young: (NS) RET older: (NS) CT young: (NS) CT older: (NS)	
	mRNA expression		
	Collagens COL1A1 COL1A2 COL3A1 COL4A1 COL4A2	↑ 370–510% ↑ 90–550% ↑ 80–540% ↑ 350–430% ↑ 280–350%	
	COL5A1 COL5A2 COL5A3 COL6A1 COL6A2	† 240–270% † 250–290% † 50% † 70% † 210%	
	COL6A3 COL8A1 COL12A1 COL14A1 COL15A1 COL18A1	† 230% † 260% † 50% † 250% † 80% † 60%	
Timmons et al., 2010 [39]	PLOD2 Proteoglycans ASPN BGN CSPG2 HSPG2	↑ 60%  ↑ 220–290%  ↑ 250–560%  ↑ 170–590%  ↑ 90%	N/A
	LUM OGN Glycoproteins AGRN	↑ 270% ↑ 420–500% ↑ 60–80%	
	LAMA4 LAMB1 LAMC1 SPARC	↑ 240% ↑ 250–270% ↑ 50% ↑ 50–250%	
	NID1 NID2 FBN1 FN1	↑ 80% ↑ 290% ↑ 50-730% ↑ 60-90%	
	TNC THBS4 POSTN PXDN FNDC1 CTHRC1	↑ 430–530% ↑ 280% ↑ 390% ↑ 220–250% ↑ 300% ↑ 340%	
Valdivierso et al., 2017 [40]	Protein expression Glycoproteins Tenascin C	A/A alleles: $\uparrow$ 138% ( $p$ < 0.05) A/T alleles: $\uparrow$ 77% ( $p$ < 0.05) T/T alleles: (NS)	Capillary/fibre↑ Capillary/fibre↑ Capillary/fibre↓15%

Cells **2021**, 10, 1022 20 of 28

Table 4. Cont.

First Author, Year of Publication	Outcome Measure	Δ ECM Outcome Post Training within Group	Association between ECM and Muscle Remodelling Outcome within the Study
	mRNA expression		M2 macrophages/fibre vs. COL5A1 expression (r = 0.56, $p = 0.021$ )
Walton et al., 2019 [41]	Collagens		M2 macrophages/fibre vs. COL6A1 expression ( $r = 0.54$ , $p = 0.026$ )
	COL5A1	↑ 53.6% ( <i>p</i> = 0.013)	M2 macrophages/fibre vs. SPARC expression ( $r = 0.63$ , $p = 0.007$ )
	COL6A1	$\uparrow$ 29.5% ( $p = 0.009$ )	M2 macrophages/fibre vs. MMP14 expression (r = 0.69, p = 0.002)
	Glycoproteins		M2 macrophages/fibre vs. TGF $\beta$ 1 expression (r = 0.50, $p$ = 0.04)
	SPARC	$\uparrow$ 56.6% ( $p$ < 0.001)	
Alghadir et al., 2016 [42]	Circulating markers (serum)		Level of cFN vs. Physical activity (PA):
	Cellular Fibronectin (or cFN)	Exercise: $\downarrow 53\% \ (p < 0.001)$	$\uparrow$ in cFN after in low PA (r = 0.18, $p < 0.001$ )
		Control: ↓ 2.1% (NS)	↑ in cFN after moderate PA (r = 0.12, $p$ < 0.001) ↑ in cFN after ↑ in high PA vs. (r = 0.14, $p$ < 0.001)
Olstad et al., 2020 [34]	mRNA expression Proteoglycans		· · · · · · · · · · · · · · · · · · ·
	DCN	Healthy: N/A Osteoporotic: ↑ 129.4%	
	Glycoproteins SPARC	Healthy: N/A	N/A
	MGP	Osteoporotic: ↑ 141.6% Healthy: N/A Osteoporotic: ↑ 128.2%	

The last two entries are from clinical populations. Data are presented as mean  $\pm$  SD (or SEM\*); lean body mass (LBM); cross sectional area (CSA); increase ( $\uparrow$ ); decrease ( $\downarrow$ ); not significant (NS); not available (N/A); change ( $\Delta$ ); serial analysis of gene expression tags (SAGE tags); resistance exercise training (RET); combined training (CT); high intensity interval training (HIIT); vastus lateralis muscle (MVL); trapezius muscle (MTRAP).



**Figure 2.** Venn diagrams of the upregulated collagens, proteoglycans and glycoproteins ECMs transcriptomes in healthy young and old participants when exercise training lasted less than or more than 9 weeks.

Cells 2021, 10, 1022 21 of 28

# 3.3. ECM Adaptation Associated with Muscle Structure and Stability

ECMs play a crucial role in muscle structure. They stabilise muscle cells by modifying the mechanical properties of the tissue, decreasing its stress and making it more load resistant. The failure of ECMs to maintain this structure results in increased susceptibility to mechanical stress and muscular fibre necrosis. Collagen fibrils provide mechanical stability to the skeletal muscle and regulate cell adhesion and differentiation. They confer tensile strength, rigidity, and compliance to the muscle [11,45]. Among the collagen superfamily, collagen I and III are present in the form of fibrils and they account for the 75% of the total skeletal muscle collagen. Exercise training promoted a widespread increase in mRNA expression of various types of collagen including COL1, COL3, COL4, COL5, COL6, COL8, COL12, COL14, COL15, and COL18 and PLOD2 in both age groups [29,30,37,39]. The increase in collagens is also shown at protein level [30], demonstrating an increase in posttranscriptional and translation events. The studies comparing younger to older participants [36,38] demonstrated a higher fold change in ECMs from older participants, which was dependent on the type of exercise modality. Robinson et al. found that older participants present greater induction of the transcriptomes for collagen IV, collagen XIV, lumican, elastin and periostin after HIIT training, but not after RT and CT [38], whereas Raue et al. demonstrate that RT induces a greater fold change of collagens, proteoglycans and glycoproteins in older participants compared to young [36].

The collagen types XV and XVIII have structural features of both collagens and proteoglycans [46]. These collagens are known to be associated with the stability of microvessels to muscle cells [47] and they were transcriptionally upregulated mainly in older subjects after CT or RET [26,36] and in young after AET [30,39].

Type IV collagen is the major constituent of the basement membrane supporting the ECM niche for satellite cells. Collagen IV forms a complex network tethering other ECM proteins, including laminins and proteoglycans, as well as growth factors and cellular receptors, as reviewed elsewhere [48]. COL4 mRNA expression was increased after all types of exercise training and in subjects of all ages at mRNA and protein level [24,26,30,36–38], including after shorter durations of AET [37]. Interestingly, HIIT induced a more than 60% increase in COL4 in older participants compared to young [38].

Among the glycoproteins, the laminin subunits were significantly increased across all the population tested at the level of mRNA [25,26,30,36,38,39] and protein [24]. Laminins are heterodimers constituted by association of three different gene products, the  $\alpha$ ,  $\beta$  and  $\gamma$  chains. LAMA4, LAMB1, LAMC1 and LAMC3 transcriptomes were upregulated after exercise, but LAM $\beta$ 3 chain was decreased in older subjects after CT [26]. At the basement membrane, laminin serves as a ligand for the sarcolema receptors of the dystrophynassociated glycoprotein complex and the  $\alpha$ 7 $\beta$ 1 integrin. In addition to its central role in the architecture and stability of the basement membrane, laminins control and trigger cellular functions by interacting with cell surface components and trapping growth factors [49]. Nidogens also contribute to the structural support of the muscle by promoting the interactions between laminin and collagens [48]. All types of exercise training significantly induced upregulation in the mRNA expression of nidogen 1 and 2, irrespective of participants' age [26,36,38,39].

Perlecan (HSPG2) is a pericellular proteoglycan found at the basement membrane and it was reportedly increased in two studies investigating young participants after AET [30,39] and in one study in older adults after CT [26]. Proteoglycans interact with elastic fibres providing tissue extensibility and resilience [50]. At transcriptional level, CT and HIIT increased elastin and elasticity-associated emilin-3 in older participants [26,38].

### 3.4. ECMs Associated with Myogenic Regeneration and Repair

A similar number of glycoproteins were identified to be upregulated in both age groups after exercise training. However, fibronectin, tenascin C and fibrillin were only reported in the young group [33,39,40]. The adhesive properties of these glycoproteins are crucial to satellite cell function promoting muscle repair and regeneration. It is un-

Cells 2021, 10, 1022 22 of 28

known why the retrieved studies did not report these glycoproteins in the muscle of older participants. One of the studies measuring serum fibronectin in older diabetic patients ( $48.8 \pm 14.6$  years old) found a 50% reduction of this protein in response to moderate aerobic training [44].

Osteonectin (SPARC) was one of the most frequently reported glycoproteins in the retrieved studies. SPARC was increased after all types of exercise stimuli, duration and age groups [26,32,34,36–39,41]. This matricellular protein is essential to tissue regeneration by contributing to myofiber metabolic homeostasis, reduction in inflammation, extracellular matrix remodelling and collagen maturation [51].

Proteoglycans are also involved in the process of skeletal muscle regeneration [52] and are upregulated after skeletal muscle damage in newly formed myotubes [53]. The mRNA expression of the small leucine-rich repeat proteoglycans (SLRPs), biglycan, asporin, osteoglycin (or mimecan), lumican, was upregulated in all age groups after various exercise interventions and durations [26,30,33,36,38,39]. At protein level, AET increased the expression of asporin, lumican and prolargin in young participants [30]. Decorin is the most abundant proteoglycan in the skeletal muscle and was reported in both age groups after training. However, in young participants, decorin was either unchanged or downregulated upon the stimulus of AET [30,31], whereas in older participants it was upregulated following a CT intervention [27] and RET in osteoporotic women [34]. The proteoglycans perlecan (HSPG2) and ECM2 were reported to be upregulated independent of age or intervention type [26,30,38,39]. Aggrecan (CSPG4) was reported to be increased when measured after CT in older participants [26]. Versican (CSPG2) was reportedly increased only after AET in young participants [39].

Glypican 4 and chondroadherin are proteoglycans reported only in the older group and were among the few ECMs downregulated after exercise training [26], while in the same study, osteomodulin and phosphacan/receptor-type protein phosphatase  $\beta$  (CSPG4) [26] were induced by CT exercise in old participants. The cell surface proteoglycan CSPG4 interacts with neurons and neural cell-adhesion molecules (N-CAM) in addition to blocking N-CAM and tenascin growth-promoting ability [46].

## 3.5. Angiogenesis

Increased capillarisation to muscle fibre ratio was seen after exercise training across age groups and a range of body mass indexes (BMI) [4,6,54]. Adhesive glycoproteins such as thrombospondins are involved in angiogenesis [55]. Combined exercise training enhanced the mRNA expression of both the anti-angiogenic thrombospondin 1 (THBS1) and the pro-angiogenic thrombospondin 4 (THBS4), but the THBS4/THBS1 fold change ratio was 1.4 [26]. Although tenascin C is upregulated as consequence of injured muscle fibre [56] and damaging eccentric contraction [57], Valdivieso et al. [40] testing young participants after AET demonstrated that A/A genotype has superior gain in muscle capillarization postexercise, as compared to the T/T genotype Tenascin C (Tn-C). In addition, exercise training upregulated perlecan in both age groups [26,30,39], indicating a pro-angiogenic effect in muscle, as this proteoglycan is known to modulate pro-angiogenic factors such as fibroblast growth factor 2 (FGF2), vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) reviewed by Iozzo et al. [46].

### 4. Discussion

In this review, evidence from 21 studies including 402 participants was analysed to investigate the effect of exercise training on intramuscular ECM composition and whether these ECMs are involved in the events of muscle adaptation and remodelling. There was a widespread increase in the expression of ECM molecules in response to exercise training stimulus. Intramuscular ECMs were altered after training interventions at the transcriptional and translational level. All types of exercise training significantly upregulated similar numbers of collagens, glycoproteins, proteoglycans. Structural ECMs are likely to be widely increased supporting muscle remodelling. While it became evident that ECMs

Cells 2021, 10, 1022 23 of 28

participate in muscle adaptation, the current evidence on the role of ECMs orchestrating particular events during remodelling was limited by lack of controlled trials incorporating mechanistic outcome measures into adequately sized human exercise training trials.

All studies demonstrated that repetitive bouts of exercise over time (training) promotes changes in muscle architecture, capillarisation and myogenesis in younger and older participants, consistent with other studies [4,13,17,54,58]. Despite the variability regarding participant sex, age and exercise type/duration, muscle remodelling was accompanied by ECM adaptation. This was mostly evident in seven studies, which associated ECM changes to specific muscle remodelling events including CSA, muscle strength, angiogenesis, as well as the level of physical activity [27,36,40–44].

Exercise is known to affect muscle in young and old adults differently. Our findings revealed that similar ECMs are increased in both age groups after exercise training. Only two studies compared the exercise training-induced ECM response in younger and older participants [36,38]. Their results were in agreement, showing that change in ECMs is towards the same direction in young and older participants. Although the fold change may be different among age groups and exercise training applied, the ECM responses are towards a similar direction. In agreement, it was observed that ECMs upregulated in early training sessions are also upregulated at later sessions. [36]. Thus, the findings indicate that in healthy adults, exercise training leads to similar ECM transcriptomes independently of age group and number of training sessions, demonstrating similar regulation in both age groups.

The ECM response is resultant of a force–time integral among the interventions tested, which may have affected the fold change of individual genes, but resulted in similar transcriptomes [59]. Further understanding of how different types of exercise cause changes in intramuscular ECMs was limited by the number of studies comparing exercise modalities [38], as AET and HIIT were mostly prescribed to younger populations and CT and RET to the older age groups. Likewise, rat skeletal muscle presented similarly increased ECM transcriptomes in response to isometric and concentric exercise training, but greater fold change was observed in response to higher mechanical stimulus [60]. Considering that the changes in gene expression after exercise in the elderly are delayed compared to younger participants [59], the tendency of applying longer training protocols to the elderly may have contributed to the observed similar ECM outcomes. In agreement with our findings, the study on acute RET bouts demonstrated that ECMs, including COL1A1, COL7A7, ADAMTS1, are upregulated in participants from both age groups [61]. Importantly, all exercise types upregulated collagen IV and laminin in both age groups. These ECMs provide critical scaffolding for the basement membrane, offering stability for the sarcolemma and myofiber cytoskeletal integrity, and the lateral transfer of mechanical force from the muscle cell to surrounding stroma ECM during contraction. The observed ECM remodelling at the basement membrane, in addition to facilitating myofiber repair, will allow the healthy expansion of intramuscular ECM to accommodate muscle fibre growth. Therefore, this systematic review demonstrates that adequate training interventions in terms of duration and intensity were applied according to age groups, and ECM adaptation accompanied muscle phenotypic remodelling [27,36,42,43].

Quiescent satellite cells which reside beneath the basal lamina can respond to mechanical stimuli and damage, becoming activated, differentiating into myoblasts that can fuse together to regenerate lost tissue or fuse with existing fibres to allow for myofiber repair [62]. This process depends on ECM composition, stiffness, topography and porosity [20]. The observed balanced composition of ECMs between age groups highlights the importance of ECMs' function not only as a supportive scaffold, but also integrating both biochemical and mechanical signalling in the stem cell niche [63]. Therefore, ECMs play a role regulating cell behaviour, dictating tissue repair, remodelling and overall function [20]. At the early stages of muscle regeneration and repair, laminin and collagen type I are downregulated. In contrast, hyaluronic acid, tenascin and fibronectin are upregulated,

Cells 2021, 10, 1022 24 of 28

forming a provisional matrix, enabling mitotic satellite cell adhesion, fusion and muscle regeneration [9].

Fibronectin, the preferred adhesive substrate for satellite cells, was reportedly increased only in young participants. Further studies on the effect of exercise training on the expression of fibronectin in the older population will be necessary to understand the importance of this glycoprotein to myogenesis. It is noteworthy that loss of muscle fibronectin in aged mice leads to ineffective muscle remodelling [64]. As satellite cells fail to adhere to fibronectin, the cells die by anoikis, demonstrating that ECM composition controls remodelling. The study also demonstrated that overexpression of fibronectin leads to rejuvenation of the skeletal muscle. In addition, fibronectin has been shown to prevent myostatin-mediated inhibition of myoblast proliferation [65,66]. Decorin is another ECM upregulated after exercise training, which is capable of inhibiting myostatin [27,34]. Myostatin regulates myogenesis and inhibits muscle mass by maintaining satellite cell quiescence. Recently, the group of Barreiro demonstrated that sarcopenic muscle from COPD patients is characterised by increased levels of myostatin compared to non-sarcopenic controls [58]. However, the levels of decorin and fibronectin in sarcopenic muscle after exercise training is not known.

Endothelial cell adhesion is mediated by the counterbalancing properties of fibronectin and tenascin-C [67]. The antiadhesive tenascin C, previously associated with muscle damage, is shown in this review to be crucial to increased capillarisation in young participants after AET postexercise training [40]. The authors concluded that the A/A genotype for tenascin C is more permissive of structural rearrangements of capillaries with respect to muscle fibres by relieving cells from the mechanical constraints of contact inhibition. For individuals carrying the T/T genotype, angiogenesis remained unchanged, suggesting that genotyping of tenascin C affects the exercise-induced level of capillarization [40].

Glypican-4 and chondroadherin are proteoglycans reported only in the older group and were among the few ECMs downregulated after exercise training [26]. The heparan sulphate proteoglycans, such as glypican-4, agrin and perlecan, are intimately associated with the plasma membrane of satellite cells functioning as major modifiers of growth factors such as FGF and VEGF. Glypican-4 also functions as an adipokine, which is associated with metabolic disease [68]. The downregulation of glypican-4 in an older group [26] is herein another supportive finding on the effect of ECM regulating muscle metabolism [68]. Increased levels of glypican-4 are associated with risk of type 2 diabetes and the prevalence of insulin resistance in these patients [69].

None of the studies compiled in this analysis included participants presenting muscle and nerve pathologies, sarcopenia, cachexia, dystrophic muscle repair, fibrosis or abnormal muscle remodelling. Nor were any damaging exercise interventions included. Thus, we can conclude that the that the observed widespread increase in ECMs reflects a physiological ECM response and adaptation to exercise training in all age groups tested.

### Strength and Limitations

To the best of our knowledge, this is the first systematic review on the effect of exercise training-induced ECM adaptations in human skeletal muscle. Only training exercise interventions which displayed a balanced insight of the post-training adaptations and repair of the muscle tissue were retained in this review. The effect of an acute bout of exercise was not the topic of this review, as that would reflect momentarily changes in ECM which may not be representative of a physiological muscle tissue adaptation, especially when considering the variability in human response. Importantly, only data from healthy adults were analysed, allowing direct translation of this research into understanding the benefits of exercise training improving muscle health. However, due to the different methodological approaches used in the studies, further data analyses were restricted. Future research on exercise training should be focused on addressing how the skeletal muscle ECM of a specific population group (e.g., sex and age) responds to a specific exercise training intervention. Deciphering the mechanisms that underlie ECM-induced skeletal

Cells 2021, 10, 1022 25 of 28

muscle adaptation will support the discovery of biomarkers of ECM adaptation, which can present itself as a novel therapeutic target, contributing to the understanding of muscle remodelling myogenic processes and supporting the use of exercise training as medicine.

## 5. Conclusions

The importance of exercise training conditioning muscle has long been recognised for its therapeutic effect in healthy adults and counteracting muscle wasting [2,58]. Recently, advances have supported better understanding of the potential of exercise training for maintaining muscle mass, strength and function during ageing. Our findings demonstrate that exercise training affects ECM composition and, consequently, adaptation and regeneration after exercise. The intramuscular ECMs, consisting of collagens, proteoglycans and glycoproteins, have a well-defined role in three-dimensional scaffolding and are also essential for effective muscle contraction and force transmission. This systematic review also points to the involvement of ECMs in myogenic and angiogenic physiological processes, and it is clear that the ECM, by interacting with various cells, can regulate exercise-induced muscle adaptation, regeneration and repair. Further studies on the effect of exercise training modifying ECMs in different age groups are necessary to better understand the crucial role of these molecules on ageing muscle. New findings on the role of ECMs will support the development of effective therapeutic approaches to support and treat muscle wasting.

**Supplementary Materials:** The systematic review search strategy for PUBMED (Table S1), and results on the changes in ECM-related molecules after exercise training intervention (Table S2) are available online at <a href="https://www.mdpi.com/article/10.3390/cells10051022/s1">https://www.mdpi.com/article/10.3390/cells10051022/s1</a>.

**Author Contributions:** Conceptualization D.C.M.S. and design D.C.M.S., E.K.; methodology, D.C.M.S., E.K., R.A. and L.W.; literature search and validation, E.K., R.A. and D.C.M.S.; analysis D.C.M.S. and E.K.; writing—original draft preparation, D.C.M.S. and E.K.; writing—review and editing, D.C.M.S., E.K., E.B., L.W. and K.P. All authors have read and agreed to the published version of the manuscript.

Funding: E.K. is a recipient of a PhD scholarship from Northumbria University Newcastle.

**Data Availability Statement:** Data used in this study were collated from peer reviewed studies. All databases were accessed via the Northumbria University library platform.

Conflicts of Interest: The authors declare no conflict of interest.

### References

- 1. Neufer, P.D.; Bamman, M.M.; Muoio, D.M.; Bouchard, C.; Cooper, D.M.; Goodpaster, B.H.; Booth, F.W.; Kohrt, W.M.; Gerszten, R.E.; Mattson, M.P.; et al. Understanding the Cellular and Molecular Mechanisms of Physical Activity-Induced Health Benefits. *Cell Metab.* 2015, 22, 4–11. [CrossRef] [PubMed]
- 2. Cruz-Jentoft, A.J.; Sayer, A.A. Sarcopenia. *Lancet* **2019**, 393, 2636–2646. [CrossRef]
- 3. Sepulveda-Loyola, W.; Osadnik, C.; Phu, S.; Morita, A.A.; Duque, G.; Probst, V.S. Diagnosis, prevalence, and clinical impact of sarcopenia in COPD: A systematic review and meta-analysis. *J. Cachexia Sarcopenia Muscle* **2020**, *11*, 1164–1176. [CrossRef] [PubMed]
- 4. Vogiatzis, I.; Stratakos, G.; Simoes, D.C.; Terzis, G.; Georgiadou, O.; Roussos, C.; Zakynthinos, S. Effects of rehabilitative exercise on peripheral muscle TNFalpha, IL-6, IGF-I and MyoD expression in patients with COPD. *Thorax* **2007**, *62*, 950–956. [CrossRef] [PubMed]
- 5. Vogiatzis, I.; Terzis, G.; Nanas, S.; Stratakos, G.; Simoes, D.C.; Georgiadou, O.; Zakynthinos, S.; Roussos, C. Skeletal muscle adaptations to interval training in patients with advanced COPD. *Chest* **2005**, *128*, 3838–3845. [CrossRef] [PubMed]
- 6. Simoes, D.C.M.; Vogiatzis, I. Can muscle protein metabolism be specifically targeted by exercise training in COPD? *J. Thorac. Dis.* **2018**, *10*, S1367–S1376. [CrossRef]
- 7. Gillies, A.R.; Lieber, R.L. Structure and function of the skeletal muscle extracellular matrix. *Muscle Nerve* **2011**, 44, 318–331. [CrossRef]
- 8. Fry, C.S.; Kirby, T.J.; Kosmac, K.; McCarthy, J.J.; Peterson, C.A. Myogenic Progenitor Cells Control Extracellular Matrix Production by Fibroblasts during Skeletal Muscle Hypertrophy. *Cell Stem Cell* **2017**, 20, 56–69. [CrossRef]
- 9. Calve, S.; Odelberg, S.J.; Simon, H.G. A transitional extracellular matrix instructs cell behavior during muscle regeneration. *Dev. Biol.* **2010**, *344*, 259–271. [CrossRef]
- 10. Street, S.F. Lateral transmission of tension in frog myofibers: A myofibrillar network and transverse cytoskeletal connections are possible transmitters. *J. Cell. Physiol.* **1983**, *114*, 346–364. [CrossRef]

Cells **2021**, 10, 1022 26 of 28

11. Csapo, R.; Gumpenberger, M.; Wessner, B. Skeletal Muscle Extracellular Matrix—What Do We Know About Its Composition, Regulation, and Physiological Roles? A Narrative Review. *Front. Physiol.* **2020**, *11*, 253. [CrossRef]

- 12. Yin, H.; Price, F.; Rudnicki, M.A. Satellite cells and the muscle stem cell niche. *Physiol. Rev.* 2013, 93, 23–67. [CrossRef] [PubMed]
- 13. Seynnes, O.R.; de Boer, M.; Narici, M.V. Early skeletal muscle hypertrophy and architectural changes in response to high-intensity resistance training. *J. Appl. Physiol.* **2007**, *102*, 368–373. [CrossRef] [PubMed]
- 14. Snijders, T.; Verdijk, L.B.; van Loon, L.J. The impact of sarcopenia and exercise training on skeletal muscle satellite cells. *Ageing Res. Rev.* **2009**, *8*, 328–338. [CrossRef] [PubMed]
- 15. Wilson, J.M.; Loenneke, J.P.; Jo, E.; Wilson, G.J.; Zourdos, M.C.; Kim, J.-S. The effects of endurance, strength, and power training on muscle fiber type shifting. *J. Strength Cond. Res.* **2012**, *26*, 1724–1729. [CrossRef] [PubMed]
- 16. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; Group, P. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *Int. J. Surg.* **2010**, *8*, 336–341. [CrossRef] [PubMed]
- 17. De Brandt, J.; Spruit, M.A.; Derave, W.; Hansen, D.; Vanfleteren, L.E.; Burtin, C. Changes in structural and metabolic muscle characteristics following exercise-based interventions in patients with COPD: A systematic review. *Expert Rev. Respir. Med.* **2016**, 10, 521–545. [CrossRef] [PubMed]
- 18. Pratt, J.; Boreham, C.; Ennis, S.; Ryan, A.W.; De Vito, G. Genetic Associations with Aging Muscle: A Systematic Review. *Cells* **2019**, *9*, 12. [CrossRef]
- 19. Roig, M.; O'Brien, K.; Kirk, G.; Murray, R.; McKinnon, P.; Shadgan, B.; Reid, W.D. The effects of eccentric versus concentric resistance training on muscle strength and mass in healthy adults: A systematic review with meta-analysis. *Br. J. Sports Med.* **2009**, 43, 556–568. [CrossRef]
- 20. Garg, K.; Boppart, M.D. Influence of exercise and aging on extracellular matrix composition in the skeletal muscle stem cell niche. *J. Appl. Physiol.* **2016**, 121, 1053–1058. [CrossRef]
- 21. Sterne, J.A.; Hernan, M.A.; Reeves, B.C.; Savovic, J.; Berkman, N.D.; Viswanathan, M.; Henry, D.; Altman, D.G.; Ansari, M.T.; Boutron, I.; et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* **2016**, *355*, i4919. [CrossRef]
- 22. Sterne, J.A.C.; Savovic, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Boutron, I.; Cates, C.J.; Cheng, H.Y.; Corbett, M.S.; Eldridge, S.M.; et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. *BMJ* **2019**, *366*, 14898. [CrossRef]
- 23. Ma, L.L.; Wang, Y.Y.; Yang, Z.H.; Huang, D.; Weng, H.; Zeng, X.T. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: What are they and which is better? *Mil. Med. Res.* **2020**, *7*, *7*. [CrossRef]
- 24. Damas, F.; Ugrinowitsch, C.; Libardi, C.A.; Jannig, P.R.; Hector, A.J.; McGlory, C.; Lixandrao, M.E.; Vechin, F.C.; Montenegro, H.; Tricoli, V.; et al. Resistance training in young men induces muscle transcriptome-wide changes associated with muscle structure and metabolism refining the response to exercise-induced stress. *Eur. J. Appl. Physiol.* 2018, 118, 2607–2616. [CrossRef]
- 25. Deshmukh, A.S.; Steenberg, D.E.; Hostrup, M.; Birk, J.B.; Larsen, J.K.; Santos, A.; Kjobsted, R.; Hingst, J.R.; Scheele, C.C.; Murgia, M.; et al. Deep muscle-proteomic analysis of freeze-dried human muscle biopsies reveals fiber type-specific adaptations to exercise training. *Nat. Commun.* **2021**, *12*, 304. [CrossRef]
- 26. Hjorth, M.; Norheim, F.; Meen, A.J.; Pourteymour, S.; Lee, S.; Holen, T.; Jensen, J.; Birkeland, K.I.; Martinov, V.N.; Langleite, T.M.; et al. The effect of acute and long-term physical activity on extracellular matrix and serglycin in human skeletal muscle. *Physiol. Rep.* 2015, 3, e12473. [CrossRef]
- 27. Kanzleiter, T.; Rath, M.; Gorgens, S.W.; Jensen, J.; Tangen, D.S.; Kolnes, A.J.; Kolnes, K.J.; Lee, S.; Eckel, J.; Schurmann, A.; et al. The myokine decorin is regulated by contraction and involved in muscle hypertrophy. *Biochem. Biophys. Res. Commun.* **2014**, 450, 1089–1094. [CrossRef]
- 28. Karlsen, A.; Soendenbroe, C.; Malmgaard-Clausen, N.M.; Wagener, F.; Moeller, C.E.; Senhaji, Z.; Damberg, K.; Andersen, J.L.; Schjerling, P.; Kjaer, M.; et al. Preserved capacity for satellite cell proliferation, regeneration, and hypertrophy in the skeletal muscle of healthy elderly men. *FASEB J.* **2020**, *34*, 6418–6436. [CrossRef]
- 29. Kern, H.; Barberi, L.; Lofler, S.; Sbardella, S.; Burggraf, S.; Fruhmann, H.; Carraro, U.; Mosole, S.; Sarabon, N.; Vogelauer, M.; et al. Electrical stimulation counteracts muscle decline in seniors. *Front. Aging Neurosci.* **2014**, *6*, 189. [CrossRef]
- 30. Makhnovskii, P.A.; Zgoda, V.G.; Bokov, R.O.; Shagimardanova, E.I.; Gazizova, G.R.; Gusev, O.A.; Lysenko, E.A.; Kolpakov, F.A.; Vinogradova, O.L.; Popov, D.V. Regulation of Proteins in Human Skeletal Muscle: The Role of Transcription. *Sci. Rep.* **2020**, *10*, 3514. [CrossRef]
- 31. Nishida, Y.; Tanaka, H.; Tobina, T.; Murakami, K.; Shono, N.; Shindo, M.; Ogawa, W.; Yoshioka, M.; St-Amand, J. Regulation of muscle genes by moderate exercise. *Int. J. Sports Med.* **2010**, *31*, 656–670. [CrossRef] [PubMed]
- 32. Norheim, F.; Langleite, T.M.; Hjorth, M.; Holen, T.; Kielland, A.; Stadheim, H.K.; Gulseth, H.L.; Birkeland, K.I.; Jensen, J.; Drevon, C.A. The effects of acute and chronic exercise on PGC-1alpha, irisin and browning of subcutaneous adipose tissue in humans. *FEBS J.* **2014**, *281*, 739–749. [CrossRef] [PubMed]
- 33. Norheim, F.; Raastad, T.; Thiede, B.; Rustan, A.C.; Drevon, C.A.; Haugen, F. Proteomic identification of secreted proteins from human skeletal muscle cells and expression in response to strength training. *Am. J. Physiol. Endocrinol. Metab.* **2011**, 301, E1013–E1021. [CrossRef] [PubMed]
- 34. Olstad, O.K.; Gautvik, V.T.; LeBlanc, M.; Kvernevik, K.J.; Utheim, T.P.; Runningen, A.; Wiig, H.; Kirkegaard, C.; Raastad, T.; Reppe, S.; et al. Postmenopausal osteoporosis is a musculoskeletal disease with a common genetic trait which responds to

Cells **2021**, 10, 1022 27 of 28

- strength training: A translational intervention study. *Ther. Adv. Musculoskelet. Dis.* **2020**, *12*, 1759720X20929443. [CrossRef] [PubMed]
- 35. Radom-Aizik, S.; Hayek, S.; Shahar, I.; Rechavi, G.; Kaminski, N.; Ben-Dov, I. Effects of aerobic training on gene expression in skeletal muscle of elderly men. *Med. Sci. Sports Exerc.* **2005**, *37*, 1680–1696. [CrossRef] [PubMed]
- 36. Raue, U.; Trappe, T.A.; Estrem, S.T.; Qian, H.R.; Helvering, L.M.; Smith, R.C.; Trappe, S. Transcriptome signature of resistance exercise adaptations: Mixed muscle and fiber type specific profiles in young and old adults. *J. Appl. Physiol.* **2012**, *112*, 1625–1636. [CrossRef]
- 37. Riedl, I.; Yoshioka, M.; Nishida, Y.; Tobina, T.; Paradis, R.; Shono, N.; Tanaka, H.; St-Amand, J. Regulation of skeletal muscle transcriptome in elderly men after 6 weeks of endurance training at lactate threshold intensity. *Exp. Gerontol.* **2010**, *45*, 896–903. [CrossRef]
- 38. Robinson, M.M.; Dasari, S.; Konopka, A.R.; Johnson, M.L.; Manjunatha, S.; Esponda, R.R.; Carter, R.E.; Lanza, I.R.; Nair, K.S. Enhanced Protein Translation Underlies Improved Metabolic and Physical Adaptations to Different Exercise Training Modes in Young and Old Humans. *Cell Metab.* **2017**, *25*, 581–592. [CrossRef]
- 39. Timmons, J.A.; Knudsen, S.; Rankinen, T.; Koch, L.G.; Sarzynski, M.; Jensen, T.; Keller, P.; Scheele, C.; Vollaard, N.B.; Nielsen, S.; et al. Using molecular classification to predict gains in maximal aerobic capacity following endurance exercise training in humans. *J. Appl. Physiol.* **2010**, *108*, 1487–1496. [CrossRef]
- 40. Valdivieso, P.; Toigo, M.; Hoppeler, H.; Fluck, M. T/T homozygosity of the tenascin-C gene polymorphism rs2104772 negatively influences exercise-induced angiogenesis. *PLoS ONE* **2017**, *12*, e0174864. [CrossRef]
- 41. Walton, R.G.; Kosmac, K.; Mula, J.; Fry, C.S.; Peck, B.D.; Groshong, J.S.; Finlin, B.S.; Zhu, B.; Kern, P.A.; Peterson, C.A. Human skeletal muscle macrophages increase following cycle training and are associated with adaptations that may facilitate growth. *Sci. Rep.* **2019**, *9*, 969. [CrossRef]
- 42. Fragala, M.S.; Jajtner, A.R.; Beyer, K.S.; Townsend, J.R.; Emerson, N.S.; Scanlon, T.C.; Oliveira, L.P.; Hoffman, J.R.; Stout, J.R. Biomarkers of muscle quality: N-terminal propeptide of type III procollagen and C-terminal agrin fragment responses to resistance exercise training in older adults. *J. Cachexia Sarcopenia Muscle* **2014**, *5*, 139–148. [CrossRef]
- 43. Kim, H.J.; So, B.; Choi, M.; Kang, D.; Song, W. Resistance exercise training increases the expression of irisin concomitant with improvement of muscle function in aging mice and humans. *Exp. Gerontol.* **2015**, *70*, 11–17. [CrossRef]
- 44. Alghadir, A.H.; Gabr, S.A.; Al-Eisa, E. Cellular fibronectin response to supervised moderate aerobic training in patients with type 2 diabetes. *J. Phys. Ther. Sci.* **2016**, *28*, 1092–1099. [CrossRef]
- 45. McKee, T.J.; Perlman, G.; Morris, M.; Komarova, S.V. Extracellular matrix composition of connective tissues: A systematic review and meta-analysis. *Sci. Rep.* **2019**, *9*, 10542. [CrossRef]
- 46. Iozzo, R.V.; Schaefer, L. Proteoglycan form and function: A comprehensive nomenclature of proteoglycans. *Matrix Biol.* **2015**, 42, 11–55. [CrossRef]
- 47. Guillon, E.; Bretaud, S.; Ruggiero, F. Slow Muscle Precursors Lay Down a Collagen XV Matrix Fingerprint to Guide Motor Axon Navigation. *J. Neurosci.* **2016**, *36*, 2663–2676. [CrossRef]
- 48. Grounds, M.D.; Sorokin, L.; White, J. Strength at the Extracellular Matrix-Muscle Interface. *Scand. J. Med. Sci. Sports* **2005**, *15*, 381–391. [CrossRef]
- 49. Gawlik, K.I.; Durbeej, M. Skeletal muscle laminin and MDC1A: Pathogenesis and treatment strategies. *Skelet. Muscle* **2011**, *1*, 1–13. [CrossRef]
- 50. Kielty, C.M.; Sherratt, M.J.; Shuttleworth, C.A. Elastic fibres. J. Cell Sci. 2002, 115, 2817–2828. [CrossRef]
- 51. Ghanemi, A.; Yoshioka, M.; St-Amand, J. Secreted Protein Acidic and Rich in Cysteine as A Regeneration Factor: Beyond the Tissue Repair. *Life* **2021**, *11*, 38. [CrossRef] [PubMed]
- 52. Brandan, E.; Gutierrez, J. Role of skeletal muscle proteoglycans during myogenesis. *Matrix Biol.* **2013**, *32*, 289–297. [CrossRef] [PubMed]
- 53. Goetsch, S.C.; Hawke, T.J.; Gallardo, T.D.; Richardson, J.A.; Garry, D.J. Transcriptional profiling and regulation of the extracellular matrix during muscle regeneration. *Physiol. Genom.* **2003**, *14*, 261–271. [CrossRef] [PubMed]
- 54. Vogiatzis, I.; Simoes, D.C.; Stratakos, G.; Kourepini, E.; Terzis, G.; Manta, P.; Athanasopoulos, D.; Roussos, C.; Wagner, P.D.; Zakynthinos, S. Effect of pulmonary rehabilitation on muscle remodelling in cachectic patients with COPD. *Eur. Respir. J.* **2010**, 36, 301–310. [CrossRef]
- 55. Stenina-Adognravi, O.; Plow, E.F. Thrombospondin-4 in tissue remodeling. Matrix Biol. 2019, 75–76, 300–313. [CrossRef]
- 56. Jarvinen, T.A.; Jozsa, L.; Kannus, P.; Jarvinen, T.L.; Hurme, T.; Kvist, M.; Pelto-Huikko, M.; Kalimo, H.; Jarvinen, M. Mechanical loading regulates the expression of tenascin-C in the myotendinous junction and tendon but does not induce de novo synthesis in the skeletal muscle. *J. Cell Sci.* 2003, 116, 857–866. [CrossRef]
- 57. Crameri, R.M.; Langberg, H.; Teisner, B.; Magnusson, P.; Schroder, H.D.; Olesen, J.L.; Jensen, C.H.; Koskinen, S.; Suetta, C.; Kjaer, M. Enhanced procollagen processing in skeletal muscle after a single bout of eccentric loading in humans. *Matrix Biol.* **2004**, 23, 259–264. [CrossRef]
- 58. Sancho-Munoz, A.; Guitart, M.; Rodriguez, D.A.; Gea, J.; Martinez-Llorens, J.; Barreiro, E. Deficient muscle regeneration potential in sarcopenic COPD patients: Role of satellite cells. *J. Cell. Physiol.* **2021**, 236, 3083–3098. [CrossRef]
- 59. Thalacker-Mercer, A.E.; Dell'Italia, L.J.; Cui, X.; Cross, J.M.; Bamman, M.M. Differential genomic responses in old vs. young humans despite similar levels of modest muscle damage after resistance loading. *Physiol. Genom.* **2010**, *40*, 141–149. [CrossRef]

Cells 2021, 10, 1022 28 of 28

60. Heinemeier, K.M.; Olesen, J.L.; Haddad, F.; Langberg, H.; Kjaer, M.; Baldwin, K.M.; Schjerling, P. Expression of collagen and related growth factors in rat tendon and skeletal muscle in response to specific contraction types. *J. Physiol.* **2007**, *582*, 1303–1316. [CrossRef]

- 61. Wessner, B.; Liebensteiner, M.; Nachbauer, W.; Csapo, R. Age-specific response of skeletal muscle extracellular matrix to acute resistance exercise: A pilot study. *Eur. J. Sport Sci.* **2019**, *19*, 354–364. [CrossRef]
- 62. Bentzinger, C.F.; Wang, Y.X.; Dumont, N.A.; Rudnicki, M.A. Cellular dynamics in the muscle satellite cell niche. *EMBO Rep.* **2013**, 14, 1062–1072. [CrossRef]
- 63. Ma, S.K.Y.; Chan, A.S.F.; Rubab, A.; Chan, W.C.W.; Chan, D. Extracellular Matrix and Cellular Plasticity in Musculoskeletal Development. *Front. Cell Dev. Biol.* **2020**, *8*, 781. [CrossRef]
- 64. Lukjanenko, L.; Jung, M.J.; Hegde, N.; Perruisseau-Carrier, C.; Migliavacca, E.; Rozo, M.; Karaz, S.; Jacot, G.; Schmidt, M.; Li, L.; et al. Loss of fibronectin from the aged stem cell niche affects the regenerative capacity of skeletal muscle in mice. *Nat. Med.* **2016**, 22, 897–905. [CrossRef]
- 65. Miura, T.; Kishioka, Y.; Wakamatsu, J.; Hattori, A.; Hennebry, A.; Berry, C.J.; Sharma, M.; Kambadur, R.; Nishimura, T. Decorin binds myostatin and modulates its activity to muscle cells. *Biochem. Biophys. Res. Commun.* **2006**, 340, 675–680. [CrossRef]
- 66. Miura, T.; Kishioka, Y.; Wakamatsu, J.; Hattori, A.; Nishimura, T. Interaction between myostatin and extracellular matrix components. *Anim. Sci. J.* **2010**, *81*, 102–107. [CrossRef] [PubMed]
- 67. Radwanska, A.; Grall, D.; Schaub, S.; Divonne, S.B.F.; Ciais, D.; Rekima, S.; Rupp, T.; Sudaka, A.; Orend, G.; Van Obberghen-Schilling, E. Counterbalancing anti-adhesive effects of Tenascin-C through fibronectin expression in endothelial cells. *Sci. Rep.* **2017**, *7*, 12762. [CrossRef]
- 68. Pessentheiner, A.R.; Ducasa, G.M.; Gordts, P. Proteoglycans in Obesity-Associated Metabolic Dysfunction and Meta-Inflammation. Front. Immunol. 2020, 11, 769. [CrossRef]
- 69. Yoo, H.J.; Hwang, S.Y.; Cho, G.J.; Hong, H.C.; Choi, H.Y.; Hwang, T.G.; Kim, S.M.; Bluher, M.; Youn, B.S.; Baik, S.H.; et al. Association of glypican-4 with body fat distribution, insulin resistance, and nonalcoholic fatty liver disease. *J. Clin. Endocrinol. Metab.* 2013, 98, 2897–2901. [CrossRef]